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Resumo 
 
 
O ferro é essencial para processos metabólicos fundamentais. Dada a sua 
natureza reactiva, a homeostasia do ferro é um processo altamente 
regulado em mamíferos. Um desequilíbrio no metabolismo do ferro tem 
sido associado a patologias como anemia, hemocromatose e doença de 
Alzheimer. Ferritina, hepcidina e transferrina são algumas das principais 
proteínas envolvidas na manutenção dos níveis de ferro no organismo. A 
Lipocalina 2 (LCN2) é uma proteína de 25 kDa pertencente à família das 
lipocalinas que tem sido descrita como participante em vários eventos 
biológicos, tais como diferenciação do rim, protecção de falha renal, 
apoptose, sobrevivência celular e resposta de fase aguda no fígado, baço, 
sangue e alguns tecidos epiteliais. Muito relevante é o facto de a LCN2 
ser capaz de se ligar a sideróforos bacterianos carregados com ferro. 
Durante infecções bacterianas, a LCN2 compete com as bactérias pelo 
ferro disponível, limitando assim a proliferação bacteriana. Este efeito 
bacteriostático enaltece o papel de LCN2 na resposta imune inata. Dada 
a capacidade de LCN2 para se ligar a sideróforos carregados com ferro e 
o facto de existirem células que conseguem capturar este complexo, a 
LCN2 tem sido proposta como proteína central num putativo mecanismo 
de entrega de ferro alternativo ao da transferrina. De maneira a 
compreender melhor o papel de LCN2 no metabolismo do ferro bem 
como na resposta imune inata, caracterizamos por análise 
immunohistoquimica o padrão de expressão da proteína em ratinho, do 
desenvolvimento fetal até um ano de idade, em condições 
controlo/fisiológicas (injecção com salino) e após estímulo inflamatório 
agudo (injecção com LPS). A expressão de LCN2 durante o 
desenvolvimento embrionário foi predominante no fígado e rim. O sinal 
da proteína persistiu em ambos os órgãos na primeira semana de vida de 
animais controlo, sugerindo uma ligação da proteína a processos de 
diferenciação e/ou desenvolvimento. No período pós natal, nos animais 
injectados com salino a imunoreactividade de LCN2 foi detectada no 
baço, timo e rim. A injecção com LPS induziu expressão de LCN2 no 
baço, rim, fígado e barreiras do cérebro. Os dados aqui apresentados 
indicam que a presença e o perfil de distribuição de LCN2 em alguns 
tecidos de ratinho são dependentes da idade e estado fisiológico.  
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Abstract 
 
Iron is essential for key metabolic mechanisms. Given its reactive nature, 
iron homeostasis is a highly regulated process in mammals. Iron 
imbalance as been associated to pathologies such as anemia, 
???????????????? ???? ???????????? ????????? ?????????? ????????? ????
transferrin are some of the key proteins involved in the maintenance of 
organism iron levels.  Lipocalin 2 (LCN2) is a 25 kDa protein from the 
lipocalin family that has been reported to participate in a broad range of 
biological events, such as kidney differentiation, protection from renal 
failure, apoptosis, cell survival and acute phase response in the liver, 
spleen, blood cells and some epithelial tissues. Importantly, LCN2 is 
capable of binding to bacterial siderophores loaded with iron. During 
bacterial infection scenarios, LCN2 competes with bacteria for iron 
resources, thus limiting bacterial proliferation. This bacteriostatic effect 
highlights the role of LCN2 in the innate immune system response. 
Given the ability of LCN2 to bind iron loaded siderophores and the 
finding that cells can uptake this complex, LCN2 has been proposed as a 
central participant in a putative transferrin-alternative pathway for iron 
delivery. In order to further understand the role of LCN2 in iron 
metabolism as well in the innate immune system response, we 
characterized through immunohistochemical analysis the protein 
expression pattern in mice, from fetal development to one year of age, 
both in control/physiological conditions (saline injection) and after an 
acute inflammatory stimulus (LPS injection). LCN2 expression during 
embryonic development was predominant in the liver and kidney. The 
protein signal persisted in both organs in the first week of life of control 
animals, thus suggesting that the protein may be linked to differentiation 
and/or development processes. In control post-natal animals LCN2 
immunoreactivity was detected in the spleen, thymus and kidney. LPS 
injection induced increased LCN2 expression in the spleen, kidney, liver 
and barriers of the brain. The present data indicates that LCN2 presence 
and distribution pattern in some mice tissues is dependent of age and 
physiological state. 
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1.1. Iron metabolism in mammals: an overview 
 Iron regulation in higher eukaryotes has been intensively studied and characterized. 
This trace element is required for fundamental biological processes that ensure cellular 
survival and viability (Hentze et al. 2004), with erythropoiesis being the most iron 
consuming process known in mammals (Chua et al. 2007). Due to its transition metal 
nature, iron is easily used in the organism major biochemical redox reactions (Nelson 
1999). However this propriety represents a potential hazard for the individual, since iron 
???????????????????????????????????????????????-??????redox reactions that can create highly 
reactive radicals that might, in last instance, damage cell genetic and protein content 
(Hentze et al. 2004). This is the case of iron overload disorders, such as hemochromatosis, 
that favor the formation of the referred hydroxyl radicals (Dunn et al. 2007). On the other 
hand, iron shortage is a hallmark feature of anemia (McLean et al. 2009). Furthermore, 
systemic iron imbalance has also been reported as a contributor for the development of 
neurodegenerative disorders such as Parkinson´s disease (Mandel et al. 2007). Both iron 
excess and deficiency can be harmful for the individual and can result in pathological 
disorders, hence the necessity of a close control of this trace element levels (Crichton et al. 
2002). In order to cope with this issue, higher organisms have evolved complex 
mechanisms that promote iron homeostasis trough uptake, storage and utilization, all of 
these highly regulated processes (Nelson 1999). 
1.1.1. Iron uptake, circulation, recycling and storage 
 A global overview of the iron cycle in the healthy adult human body is depicted in 
Figure 1. A healthy human male body contains about 3,5 grams of iron (Muñoz et al. 
2009). Dietary iron absorption accounts only for a small percentage of the body iron needs. 
The dietetic uptake occurs at the apical membrane of intestinal mucosa cells (enterocytes), 
with the absorption rate being dependent on body iron needs (Chua et al. 2007). Two 
different forms of iron are found to be captured by enterocytes. The majority of the 
captured iron (90%) is in an oxidized Fe
3+
 form (non-heme iron). The remaining iron 
(10%) that is captured is associated with heme protein (heme iron).  
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 The absorption of these iron forms by the intestinal enterocytes occurs through 
different mechanisms (Figure 2). Before cellular uptake, non-heme iron is reduced from 
Fe
3+
 to Fe
2+ 
by duodenal cytochrome b (DCYTB) (McKie et al. 2001).  Reduced iron then 
enters the cell through the divalent metal transporter 1 protein (DMT1) (Figure 2). On the 
other hand, heme iron is likely captured by a putative heme carrier protein 1 (HCP1) and 
Figure 1  Systemic iron distribution. Dietary iron absorption occurs at the intestine and accounts for a small 
proportion of the organism iron needs. Iron that circulates in the plasma is bound to transferrin. Most of this 
available iron is used in erythrocytes formation which occurs in the bone marrow. Indeed, erythropoiesis is the 
most iron consuming process of the organism, with the majority of the body iron being present in the erythrocytes 
hemoglobin. Senescent or damaged erythrocytes are phagocyted by macrophages of the reticuloendothelial 
system which can either store or release the recycled iron into circulation. The quantity of recycled iron that is 
released by these macrophages is similar to the iron that is consumed in erythropoiesis. Besides macrophages, 
liver hepatocytes also store iron, with the metal being retrieved from those cells according to the body needs. Iron 
is also required for the normal functioning of diverse tissues such as muscle fibers. Residual iron losses occur 
through various processes including skin desquamation, sloughed intestinal cells and blood losses. Adapted from 
Anderson et al. (2007). 
 
 
Erythrocytes hemoglobin 
~2300 mg iron 
Liver storage 
~200 mg iron 
 
 
Macrophage 
storage 
~500 mg iron 
 Transferrin-bound 
iron 
~3 mg iron 
Iron recycling 
~22 mg iron/day 
 
Bone marrow 
~150 mg iron 
Other cells (eg. Muscle) 
~350 mg iron 
Iron losses: 
Urine 
Desquamation 
Menstruation 
Sloughed intestinal 
cells Blood losses 
~1-2 mg iron/ day 
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once within the cell, it is believed that iron is dissociated from the heme protein into the 
ferrous form (Fe
2+
) mainly by heme oxygenase 1 (Hox1) (Kikuchi et al. 2005) (Figure 2). 
This iron presumably shares the same destinations as the absorbed non-heme iron (Muñoz 
et al. 2009). Once inside the mucosa cell, iron can remain in a labile iron pool (which is 
ready for immediate utilization by the cell), be stored within ferritin or exported into blood 
circulation throughout the only known iron exporter, ferroportin (FPN) (Breuer et al. 2008; 
Chua et al. 2007; Kakhlon 2002; Muñoz et al. 2009). 
 
 
 
 
 
 
 
 
 Just before entering circulation, iron is oxidized by the ferroxidase hephaestin 
(Vulpe et al. 1999). Fe
3+
 then rapidly binds with its main transporter, transferrin. 
Transferrin is the chief protein responsible for the transport and delivery of iron into the 
majority of cells (Gomme et al. 2005). The protein has two binding sites for the metal. 
Therefore, plasmatic transferrin can be apo-transferrin (no iron bound to the protein), 
monoferric transferrin and diferric transferrin. The protein is then recognized by transferrin 
receptor 1 (TfR1), a protein present in the cell membrane of most of the organism cells, 
Figure 2  Iron absorption in the enterocyte. Heme iron constitutes a minority of the absorbed iron by the intestinal 
tract. This iron likely enters enterocytes through heme carrier protein 1 (HCP1) and once within the cell it is released 
by heme oxygenase 1 (Hox1) in the form of Fe2+. This iron then enters in the transit (labile) iron pool. Non-heme iron 
is reduced by duodenal cytochrome b (DCYTB) to then enter the cell through DMT1.This iron also joins the transit 
iron pool. From there iron can either be stored as ferritin or exported to the bloodstream by ferroportin (FPN). Iron is 
then oxidized by hephaestin to afterwards bind to transferrin, the metal main transporter. All abbreviations can be 
found on page 7. Adapted from Trinder et al. (2002). 
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which mediates the endocytosis of the transferrin-iron complex. TfR1 has higher affinity 
for the diferric form of transferrin (Huebers and Finch 1987). Once engulfed, vesicle pH is 
acidified by injection of H
+
 by proton bombs, which in turn promotes the dissociation of 
iron from transferrin. Afterwards iron leaves the endosome via DMT1 transporter into the 
cytoplasm to be used in diverse cellular processes. Transferrin and TfR1 are then recycled 
to cell surface for posterior usage (Chua et al. 2007; Crichton et al. 2002; Hentze et al. 
2004). Most organism cells uptake transferrin loaded iron through this TfR1 mediated 
endocytosis mechanism (Hentze et al. 2010).Another transferrin receptor, homologous to 
TfR1, was first described by Kawabata et al. (1999). Transferrin receptor 2 (TfR2) is 
mainly expressed in the liver hepatic cells and although it binds transferrin with a lower 
affinity than TfR1, the cellular uptake mechanism of the transferrin-iron complex trough 
this receptor is similar to the one described for TfR1. Despite the functional and structural 
homology between the receptors, in TfR1 absence scenarios, TfR2 is not capable of 
ensuring basal cell iron uptake needs (Chua et al, 2007). 
 The levels of dietary iron absorption are identical to the losses of the metal that 
occurs through events such as skin desquamation, menstruation and sloughing of intestinal 
mucosal cells (Figure 1). Hence, iron intake by the intestine is not sufficient to ensure the 
full iron needs of the organism. Indeed, most of the iron required for the regular 
functioning of the organism is obtained through recycling of senescent erythrocytes. In a 
healthy human, the majority of the body iron (65-70%) is contained in the red blood cells 
(RBC) hemoglobin (Anderson et al. 2007). The generation of RBC, a process termed 
erythropoiesis that normally occurs in the bone marrow, is the most iron consuming 
phenomena in the organism. Most of the iron required to ensure physiological 
erythropoiesis is resultant from recycling of the metal from dying or damaged erythrocytes 
by macrophages of the reticuloendothelial system. Once inside the macrophage, iron is 
dissociated from hemoglobin and similarly to what happens in enterocytes, it can either be 
stored in the cell as ferritin, remain in the labile iron pool or exported trough FPN into 
circulation where it binds to transferrin (Muñoz et al. 2009). A smaller proportion of the 
body iron (10-15%) is contained in proteins such as myoglobin, NADP dehydrogenase and 
ferredoxins. The remaining iron (20%) is stored mainly in the reticuloendothelial system 
macrophages and in the liver hepatocytes. The majority of this stored iron is ferritin bound 
(Anderson et al. 2007; Muñoz et al. 2009; Nadadur et al. 2008). 
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Regulation of body iron levels involves diverse organs and tissues (Figure 1). 
Kidney participation in iron metabolism processes has been gathering increasing interest, 
with a growing body of evidence now underlining the importance of the organ in iron 
homeostasis. Accordingly to Smith and Thévenod (2009), approximately 99% of the iron 
that is filtered in the glomeruli is later reabsorbed in the nephron. The metal uptake appears 
to occur in proximal tubules (PT) and distal segments of the nephron (Wareing et al. 2000). 
Concordantly, some of the key iron related proteins have been found to be expressed in the 
organ.  
One of those proteins is DMT1, the main iron importer in the duodenum, which is 
present in the PT and collecting ducts of rodents (Canonne-Hergaux and Gros 2002; 
Ferguson et al. 2001; Veuthey et al. 2008). Interestingly, the intra-cellular location of 
DTM1 in the PT appears to differ between rat and mice, with the protein being present in 
late endosomes and lysosomes in rat (Abouhamed et al. 2006), while in mice it was 
detected in the apical side of the cells (Canonne-Hergaux and Gros 2002; Veuthey et al. 
2008). Although more work is required to clarify these apparently contradictory 
observations, the apical localization of DMT1 in PT supports the concept of DMT1 as an 
iron uptake protein in the kidney (Canonne-Hergaux and Gros 2002; Veuthey et al. 2008). 
Furthermore, and similar to what was reported in the duodenum (Yeh et al. 2000), the 
DMT1 expression in the rat kidney is affected by dietary iron intake, with iron-rich diets 
resulting in lower DMT1 expression, while iron-restricted diets resulted in the opposite 
effect. Urinary iron levels were also found altered after the dietary manipulation (Wareing 
et al. 2003). Concomitantly, anemic mice demonstrated an evident increase in DMT1 
staining in kidney medulla, with iron deposits being found in some PT (Veuthey et al. 
2008). Taken together, these data strongly suggests that DMT1 is involved in iron 
reabsorption at the kidney level. 
Another iron-related protein that has been reported to possibly participate in the 
recapture of iron from the glomerular filtrate is transferrin. Transferrin, the organism main 
iron transporter, is small enough to be filtrated by some pores of the glomeruli (Smith and 
Thévenod 2009). Indeed, residual quantities of the protein are found in the urine of normal 
subjects (Burne et al. 1999; Sawazaki et al. 1992). Transferrin reabsorption occurs in the 
apical membrane of PT of the nephron, in a process mediated by the cubilin receptor 
(Kozyraki et al. 2001). Also, the presence of the transferrin receptor TfR1 in the apical side 
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of mouse PT suggests that this receptor may mediate the recapture of transferrin from the 
filtrate, although no concrete evidence supporting this hypothesis exists (Zhang et al. 
2007). Given the high affinity of transferrin to iron, practically all of the circulating iron is 
bound to transferrin. It is then highly likely that the transferrin that is recaptured by the PT 
is loaded with iron, hence delivering the metal to the PT cells (Smith and Thévenod 
2009)(Kozyraki et al. 2001). 
While DMT1 and cubilin hypothetically recapture iron from the glomerular filtrate, 
FPN, the organism main iron exporter that is expressed by various cells types (Veuthey 
and Roque 2009), was found present in PT cells, suggesting that the protein may export 
iron into the bloodstream (Veuthey et al. 2008). These authors also observed that under 
anemic conditions there is a strong increase of FPN signal in the basal membrane of the 
PT, an evidence that further supports the role of the protein as an iron exporter in the 
kidney. Interestingly, one of the modulators of FPN expression, hepcidin (Nemeth and 
Ganz 2009), is also found expressed in the kidney (Veuthey et al. 2008). Whereas in 
healthy animals hepcidin is strongly expressed in PT cells, during anemia there is an 
evident reduction of the hepcidin signal in those tubular structures. This pattern of 
expression suggests that, similar to what happens in other tissues, hepcidin may act as a 
negative regulator of FPN in the PT cells (De Domenico et al. 2007; Veuthey et al. 2008), 
thus possibly controlling the export of iron from the nephron into blood circulation.  
Taking these data in consideration, it becomes evident that the kidney may have a 
more important role in iron homeostasis than until recently expected. Alteration in the 
expression of iron transporting proteins such as DMT1 and FPN in situations where iron 
demand is higher, such as in anemia and iron-deprived diet clearly suggests that there is a 
re-uptake of the metal from the glomerular filtrate, with this iron likely being freed back 
into systemic circulation. 
1.1.2. Regulation of iron homeostasis 
As referred above, iron imbalance can be hazardous for the organism. Given that 
mammals do not possess efficient mechanisms for the excretion of the metal, the regulation 
of the body iron levels must be tightly controlled. This regulation occurs in all steps of iron 
handling, from intestinal absorption of the metal to its cellular utilization. The homeostasis 
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of iron takes place both at the cellular and at the systemic levels, with several molecules 
and mechanisms being responsible for the modulation of key iron related proteins (Hower 
et al. 2009).   
1.1.2.1. Cellular iron metabolism 
Mammalian cells require iron for key metabolic processes. Cells can acquire, use, 
store and export iron, processes that are controlled by various proteins such as DMT1, 
ferritin and FPN. The modulation of those iron related proteins by the cell can occur at 
transcriptional, post-transcriptional and post-translational levels.  
Regulation of some iron related genes at a transcriptional level can respond not only to 
cellular iron levels but also to factors such as cytokines, lipopolysaccharide (LPS) and 
hypoxia. For instance, inflammatory cytokines such as tumor necrosis factor-alpha (TNF-
?) and interleukin-2 are found to up-regulate the mRNA expression of ferritin in diverse 
mammal cells (Torti et al. 2002). Likewise, interleukin-6 (IL-6) can regulate hepcidin 
mRNA synthesis (Lee et al. 2005). 
The post-transcriptional regulation of iron metabolism-related genes is considered 
essential for the maintenance of adequate cellular iron load and is centered in the iron 
responsive element/ iron regulatory protein (IRE/IRP) system. IRPs bind to IREs, which 
are hairpin loops present in untranslated regions (UTR) of iron-related proteins mRNAs. 
The translation outcome of this binding is dependent of the positioning of IRE in either 
5´or 3´UTR of the target mRNA. Hence, if IRP binds to the IRE at the 5´-UTR of the 
target gene, the translation of the gene gets inhibited. On the other hand, the formation of 
IRP/IRE complex in the 3´-UTR of the gene leads to a higher stability of the target mRNA, 
resulting in higher gene expression (Muckenthaler et al. 2008). Proteins such as ferritin and 
FPN possess IRE at the 5´-UTR of their mRNA, while in Tfr1 and DMT1 mRNA the IRE 
is at 3´-UTR (Chua et al. 2007).  
The binding activity of IRP to IRE is dependent of the intracellular iron levels, 
namely of the labile iron pool status. There are two homologous forms of IRP in the 
mammalian cells, IRP1 and IRP2, and whereas both proteins bind to IRE, the mechanism 
by which iron modulates this binding activity is distinct between IRPs. Hence, if cellular 
iron levels are high, IRP1 complexes with an iron-sulfur cluster, resulting in the protein 
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inability to bind IRE. Simultaneously, IRP2 is targeted for proteosomal degradation, which 
leads to lower IRP2 levels in the cell. On the other hand, if iron levels are low, both IRPs 
are available to bind IREs (for review see Hower et al. (2009)).  
Post transcriptional modulation of various iron related proteins by the IRP/IRE 
system has been demonstrated. In cellular iron depletion scenarios, IRPs binding to 5´-
UTR IRE proteins such as ferritin and FPN decreases the translation of both proteins, 
whereas IRP binding to 3´-UTR IRE of Tfr1 stabilizes the protein transcript. This results in 
increased iron uptake from the extra cellular medium as well decreased export of the metal. 
Consequently, iron concentration in those cells increases. Conversely, when cells are iron 
replete, IRPs lose their IRE binding capability. As a result, ferritin expression increases 
and the opposite occurs to Tfr1, thus preventing additional entrance of the metal into the 
cell (Muckenthaler et al. 2008; Viatte et al. 2009). Although a DMT1 isoform is reported to 
possess an IRE in the 3´UTR of the protein mRNA transcript, there is no concrete evidence 
that the protein expression is modulated by the IRE/IRP system (Hentze et al. 2010). 
It is important to notice that the majority of these molecular mechanisms were 
found and described in in vitro work. However, increasing in vivo evidence support the 
relevance of these mechanisms in cellular iron homeostasis (Ferring-appel et al. 2009; 
Galy et al. 2008; Gnana-Prakasam et al. 2010; Muckenthaler et al. 2008). It is also 
noteworthy that, despite the presence of IRPs in renal PT, the role of the IRE/IRP system 
in the regulation of iron related molecules in the kidney remains unclear (Muckenthaler et 
al. 2008).  
Besides transcriptional and post-transcriptional regulation, some iron related 
proteins such as TFR2 and FPN were found to be regulated after translation of the 
respective transcripts (Johnson and Enns 2004; Yeh et al. 2000). Details of FPN post-
translational regulation by hepcidin will be described below.  
1.1.2.2. Systemic regulation of iron metabolism: The hepcidin model. 
As described above, cells can manage their own levels of iron through the 
regulation of iron related proteins. Adequate iron levels at the systemic level must be 
ensured by coordinated regulation of iron absorption, storage and recycling. Hence, 
feedback mechanisms must exist in order to balance those different activities in accordance 
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to the organism iron needs. Growing evidence suggests that at the axis of such mechanism 
is hepcidin.  
Hepcidin is a liver produced hormone that displays anti-microbial characteristics 
(Park et al. 2001). The first evidence on the importance of hepcidin in iron metabolism 
came from work with transgenic mice that lacked the hepcidin gene as a consequence of 
the knocking-out of a neighbor gene. Those mice presented a hemochromatosis phenotype, 
with iron deposition occurring in the liver and pancreas (Nicolas et al. 2001). Since then, 
the understanding on the biology of hepcidin increased greatly and the protein is now 
considered pivotal in the systemic regulation of iron (Hentze et al. 2010). 
Hepcidin acts by binding to the iron exporter FPN which is present in enterocytes, 
macrophages and hepatocytes, promoting the internalization and degradation of the 
exporter, which results in the inhibition of iron release from those cells (Figure 3). 
Consequently, serum iron levels decrease. Hepcidin thus acts as a negative regulator of 
iron export from the above mentioned cells (Nemeth et al. 2004; Ramey et al. 2010). 
Hepcidin expression levels can respond to a variety of factors. Iron overload or 
inflammatory stimulus results in increased expression of hepcidin and consequent 
diminution of iron export from enterocytes, macrophages and hepatocytes (Lee et al. 2005; 
Muñoz et al. 2009; Pigeon et al. 2001) (Figure 3). On the other hand, the expression of 
hepcidin is found to be down-regulated when the body requires higher amounts of 
available iron, which is the case in anemic condition, hypoxia and increased erythropoiesis 
(Frazer et al. 2002; Frazer et al. 2004; Millard et al. 2004) (Figure 3). This group of 
evidence supports hepcidin as a major regulator of mammalian iron metabolism.  
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The adequate expression of hepcidin is essential for the maintenance of the 
organism iron homeostasis. Hepcidin deregulated expression is associated to some iron 
related pathologies (Nicolas et al. 2001; Nicolas et al. 2002). As referred above, various 
factors can influence hepcidin expression and details of the molecular pathways behind 
such expression modulation have been unveiled (for review, see Viatte and Vaulont (2009) 
and Hentze et al. (2010)). Thus, hepcidin induction by inflammation was found to be 
dependent of the activation of the JAK/STAT3 pathway by IL-6 (Wrighting and Andrews 
2006). On the other hand, hepcidin expression is decreased by erythroid precursor protein 
GDF15 (Tanno et al. 2007), although the molecular pathway responsible for this regulation 
is still unknown. The control of hepcidin expression by systemic iron levels appear to rely 
on different molecules and mechanisms. For instance, there is evidence that suggest that 
hemochromatosis (HFE), the principal responsible for the iron overloading disorder 
hereditary hemochromatosis, promotes hepcidin synthesis in hepatocytes through the 
Figure 3  Systemic iron regulation. Regulation of iron influx occurs in all steps of the metal handling, from intestinal 
absorption to its cellular utilization. Details of those processes are discussed in the text. The maintenance of adequate iron 
levels at the systemic level is ensured by the liver produced hepcidin. Hepcidin acts through binding to the iron exporter 
ferroportin, which is present at the surface of enterocytes, splenic macrophages and hepatocytes. This binding promotes 
the exporter internalization and degradation. Consequently, iron is not exported by those cells. In iron overload scenarios 
(left), increased hepcidin expression by hepatocytes results in reduced iron export by hepatocytes, macrophages and 
enterocytes. Conversely, when iron levels are low (right), hepcidin synthesis is decreased, allowing ferroportin to export 
iron into circulation. All abbreviations can be found on page 7. Reproduced with permission from Hentze et al.(2010). 
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formation of a HFE-TfR2 complex in response to high plasmatic iron levels (Hentze et al. 
2010). However, growing evidence suggest that the bone morphogenetic protein / son of 
mother against decapentaplegic (BMP/SMAD) signaling pathway is the key mechanism of 
hepcidin modulation by systemic iron. Indeed, bone morphogenetic protein 6 (BMP6), 
whose expression is iron-dependent (Kautz et al. 2008), was recently reported as being a 
major regulator of hepcidin expression. Meynard et al. (2009) and Andriopoulos et al. 
(2009) demonstrated that BMP6 induces hepcidin expression in hepatocytes through the 
BMP/SMAD pathway, with BMP6-null mice presenting residual hepcidin expression and 
consequent organ iron accumulation. Although further work is required in order to 
understand how BMP6 expression is modulated by iron, these novel findings recognize 
BMP6 as a new master regulator of iron metabolism.  
1.2. Lipocalin 2, a new member in the iron metabolism proteins family 
In normal conditions, the intake of iron in most of the cells occurs through the 
previously described transferrin pathway. However, growing evidence suggests the 
presence of alternative mechanisms for the delivery of the metal into the cells. Studies with 
transferrin deficient mice (hypotransferrinemic) demonstrated that despite the incidence of 
anemia and deficiency in the central nervous system development, most of the epithelial 
organs are normal in this mouse strain (Yang et al. 2002). These animals also accumulate 
iron in the liver. Together, these facts support the presence of alternative pathways to 
transferrin-dependent cellular iron uptake. The participants and modus operandi of those 
mechanisms remain largely elusive. At the core of one of those putative mechanisms is 
lipocalin 2 (LCN2). 
The lipocalin family comprises a heterogeneous group of proteins that share tertiary 
structure and regions of sequence homology. Lipocalins are transporters of small 
hydrophobic ligands and have been linked to various biological processes (Grzyb et al. 
2006). LCN2, also known as 24p3 or neutrophil gelatinase-associated lipocalin (NGAL), is 
a 25 kDa sized lipocalin that was first reported in human neutrophils (Kjeldsen et al. 1993). 
Homologous forms of the protein were later confirmed in rodents (Kjeldsen et al. 2000). 
Key features of LCN2 are its ability to bind iron loaded siderophores (small molecular 
chelators secreted by bacteria) and its participation in iron trafficking (Devireddy et al. 
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2005; Goetz et al. 2002; Yang et al. 2002). We will next consider the functions of LCN2 in 
further detail.  
1.2.1. Mechanism of action of LCN2 in iron delivery 
The importance of LCN2 in iron related processes was first demonstrated by Yang 
et al. (2002) that showed that LCN2 promotes the conversion of rat metanephric 
mesenchyma into epithelia, through cellular iron delivery by a transferrin alternative 
pathway. It was also apparent that the internalization of either transferrin or LCN2 was 
dependent of the organ developmental phase, with earlier epithelial progenitors 
incorporating LCN2 while the further staged epithelial cells internalized mainly transferrin 
(Yang et al. 2003). Furthermore, the authors also demonstrated in cultured cells that iron 
delivery by LCN2 regulates iron-responsive genes, such as ferritin and TfR1. Surprisingly, 
LCN2 knockout mice present normal kidney function, thus suggesting that LCN2 mediated 
iron delivery is not crucial for the organ development (Berger et al. 2006). Together, these 
data indicates that at least part of the biological significance of LCN2 is linked to its 
capacity to bind iron. 
LCN2 does not bind to iron directly. Instead, the protein conjugates with small 
compounds that chelate the metal, such as the bacterial siderophore enterobactin (Goetz et 
al. 2002). A putative mechanism of LCN2 mediated iron traffic was later proposed by 
Devireddy et al. (2005). In experiments using modified HeLa cells it was shown that LCN2 
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pool depending on the LCN2 iron status. Fundamental to this behavior is the presence of a 
LCN2 cell surface receptor, 24p3R. Hence, once siderophore iron loaded LCN2 (Holo-
LCN2) is recognized by 24p3R, it gets internalized by receptor-mediated endocytosis. The 
bound iron is afterwards released, leading to an increase in the intra cellular iron 
concentration. On the other hand, 24p3R can also uptake LCN2 with no iron and 
siderophore bound to it (Apo-LCN2). After internalization, the protein associates with a 
putative intra-cellular siderophore which, in turn, is bound to intracellular iron. This 
complex is then excreted to extracellular space, resulting in a diminished intra-cellular iron 
concentration (Devireddy et al. 2005).  
22 
 
Questions relative to this model of iron delivery persist. Of special importance is 
the origin and nature of the putative eukaryotic siderophore. It is well established that 
bacteria produce siderophores, but the same does not apply to eukaryotic cells as there is 
no evident proof that eukaryotic cells synthesize siderophores (Richardson 2005; Schmidt-
Ott et al. 2007). The biological relevance of this mechanism in physiological conditions 
such as organ development thus remains unclear, since no bacterial siderophore is present 
in those circumstances. The isolation of a putative eukaryotic siderophore or homologous 
compound is then critical for further understanding and validation of this iron delivery 
pathway. 
1.2.2. LCN2 and immunity 
In earlier reports LCN2 was found constitutively expressed in tissues that are 
exposed to external environmental pressures, such as the gut and pulmonary tract 
(Cowland and Borregaard 1997; Friedl et al. 1999). It was later found that inflammatory 
stimulus induces acute LCN2 expression in the lung (Sunil et al. 2007), primary cultures of 
skin epithelia (Cowland et al. 2003), adipocytes (Sommer et al. 2009), macrophages (Flo et 
al. 2004) and epithelial cells of the choroid plexus (Marques et al. 2008). This acute 
response to an inflammatory stimulus is even more evident in the liver, suggesting that this 
organ is the major producer of the protein (Flo et al. 2004) under these conditions. This 
prompt and ubiquitous response lead researchers to hypothesize that LCN2 could somehow 
be part of the innate immune response mechanisms. Bacteria require iron for growth and 
proliferation in an infection setting. To cope with this need, bacteria produce siderophores 
that harvest iron resources from the host (Neilands 1995). Hence, and due to its high 
affinity for siderophores, LCN2 competes with the pathogen for iron, thus restraining the 
bacteria propagation in vitro (Goetz et al. 2002). This bacteriostatic effect of LCN2 was 
later demonstrated in vivo by Flo et al. (2004) and Berger et al. (2006); it was shown that 
LCN2 deficient mice injected with Escherichia coli presented higher bacteraemia and 
bacterial counts in the liver and spleen when compared to wild type animals. The mortality 
rates due to sepsis were also higher in knockout animals. Hence, LCN2 exerts a role in 
antibacterial iron-depletion mechanisms of the innate immune system. This effect also 
provides a plausible explanation for the basal expression of the protein in the respiratory 
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and intestinal tract. Up-regulation of LCN2 protein has also been found in various 
inflammatory conditions such as inflammatory bowel disease, appendicitis and 
diverticulitis (Nielsen et al. 1996). 
1.2.3. Other functions of LCN2 
1.2.3.1. LCN2 in the healthy and injured kidney 
As discussed before, LCN2 appears to participate in kidney development through 
iron delivery to immature renal epithelia. The role of the protein in the normal functioning 
of the mature kidney remains, however, unclear. Nevertheless, there is some evidence 
sustaining that LCN2 may also deliver iron into the healthy kidney. LCN2 is a protein 
small enough to be easily filtrated by the glomeruli. Despite that, residual levels of LCN2 
are found in the urine (Mori et al. 2005; Yang et al. 2003), suggesting that most of the 
protein is recaptured in the nephron. Indeed, intraperitoneally injected exogenous LCN2 is 
promptly cleared from the blood by kidney PT cells, with a small fraction of the injected 
protein being excreted into the urine (Mori et al. 2005). Concomitantly, the putative LCN2 
receptor megalin is expressed in the PT cells and megalin deficient mice excrete higher 
quantities of LCN2 to the urine (Mori et al. 2005), indicating that megalin may indeed 
mediate the intake of LCN2 in the PT. Expression of 24p3R, another putative LCN2 
receptor, has not been described in the kidney. Furthermore, Mori et al. (2005) also 
reported that shortly after intraperitoneal injection with 
55
Fe-loaded LCN2, most of the 
radioactive iron was found concentrated along the apical side of mice kidney PT cells. 
Whereas this group of data demonstrates that exogenous LCN2 filtrated by the glomeruli is 
captured by PT and delivers iron into the kidney, there is no concrete evidence that the 
endogenous protein exerts identical functions in healthy individuals.  
Much attention has been given to LCN2 in the context of acute kidney injury 
(AKI). LCN2 is massively up-regulated in the mouse kidney, serum and urine during 
ischemia-reperfusion injury (Mori et al. 2005; Schmidt-Ott et al. 2007). Administration of 
nephrotoxins also induces strong LCN2 expression in the kidney of rodents (Mishra et al. 
2004; Mori et al. 2005; Wang et al. 2008). In humans, the up-regulation of LCN2 in the 
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serum and/or urine following conditions such as kidney transplantation, cardiac surgery, 
haemolytic uraemic syndrome and sepsis correlates positively with AKI development 
(Mishra et al. 2005; Mishra et al. 2006; Mori et al. 2005; Trachtman et al. 2006; Wagener 
et al. 2006; Wheeler et al. 2008). Furthermore, increased LCN2 expression in renal tissue 
shortly after renal transplantation predicts AKI (Mishra et al. 2006). Concomitantly, in 
AKI scenarios LCN2 is detected in blood and urine earlier than creatinine, one of the most 
commonly used biomarkers for kidney damage (Devarajan 2008a). Therefore, LCN2 is 
regarded as a promising biomarker for early detection of kidney injury, with effective 
clinical applications in perspective (Devarajan 2008; Di Grande et al. 2009; Mori and 
Nakao 2007). Some reports also demonstrate that LCN2 is a marker of chronic kidney 
disease, reflecting the severity of the renal damage (Bolignano et al. 2008; Kuwabara et al. 
2009; Mitsnefes et al. 2007).  
The biological relevance of LCN2 in the context of renal injury remains relatively 
unclear. The existing evidence proposes that LCN2 exerts a protective effect in the injured 
kidney. Indeed, injection of exogenous LCN2 either before or after ischemia-reperfusion 
injury attenuates the organ damage (Mishra et al. 2004; Mori et al. 2005). Pivotal to this 
effect appears to be the delivery of iron to the kidney PT by LCN2. Furthermore, LCN2-
siderophore-iron complex capture by the PT cells results in higher expression of local 
Hox1, an enzyme that protects the renal epithelia from diverse damage (Jarmi and Agarwal 
2009) and rescue of the epithelial marker N-cadherin (Mori et al. 2005). The up-regulation 
of Hox1 by LCN2 appears to be crucial to the LCN2 mediated protective effect, with Hox1 
inhibition resulting in the neutralization of this LCN2 activity (Mori et al. 2005). It must be 
noticed that the origin of the LCN2 protein present in the PT after the ischemic injury is 
probably extra-renal. Indeed, in AKI scenarios the LCN2 mRNA is found up regulated in 
the lungs and liver, which may secrete the protein into circulation (Devarajan 2010; 
Schmidt-Ott et al. 2006). Hence, the observed LCN2 signal in the kidney PT is most likely 
resultant from systemic LCN2 reabsorption of the glomerular filtrate (Mori et al. 2005). 
  On the other hand, in the AKI setting the renal synthesis of LCN2 mRNA occurs 
mainly in the distal portion of the nephron, namely in the colleting ducts and loop of henle 
(Schmidt-Ott et al. 2006). As a significant portion of this locally produced LCN2 appears 
to be excreted into the urine, it is plausible that LCN2 may exert bacteriostatic functions in 
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the distal portion of the urinary tract (Mori et al. 2005; Schmidt-Ott et al. 2006; Schmidt-
Ott et al. 2007).  
In summary, the existing data indicates that LCN2 in the injured kidney may act at 
two levels. Thus, LCN2 captured from glomerular filtration may promote PT survival, 
hence attenuating the renal damage. On the other hand, LCN2 synthesized in the distal 
portion of the organ eventually protects lower urogenital tract from bacterial infections 
(Schmidt-Ott et al. 2006; Schmidt-Ott et al. 2007). 
1.2.3.2. LCN2 in cell survival and apoptosis 
Increasing evidence suggests that LCN2 exerts other functions other than iron 
trafficking and infection modulation. Diverse studies report that LCN2 displays 
contradicting effects in cell survival modulation. The work of several authors supports 
LCN2 as an apoptotic facilitator, at least in in vitro systems (Devireddy et al. 2005; Lee et 
al. 2007; Lee et al. 2009; Leng et al. 2008; Miharada et al. 2005; Miharada et al. 2008; 
Tong et al. 2003). Interestingly, some of these works indicate that the iron transport ability 
of the protein is linked to this pro-apoptotic behavior. Devireddy et al. (2005) 
demonstrated that the lipocalin-mediated depletion of intra-cellular iron resulted in the up-
regulation of the pro-apoptotic Bcl-2-interacting mediator of cell death (BIM) protein, 
accompanied by an apoptotic phenotype. Identical conclusions were obtained in work with 
astrocytes, where the cell death sensitization activity of the lipocalin was abolished by the 
presence of siderophore-iron complexes. An increased BIM expression after LCN2 
treatment was also detected in those cells (Lee et al. 2009).  
Apoptosis is a highly regulated process that can be influenced by endogenous and 
exogenous factors. It is possible that rather from being directly pro-apoptotic, LCN2 may, 
in certain circumstances, increase the cellular death by modulating the availability of 
signaling factors (Kehrer 2009). The apoptotic effect of LCN2 can also be adjusted by the 
organism necessities. Accordingly, some authors propose that LCN2 putative regulation of 
the hematopoietic process (trough apoptosis and inhibition of cell differentiation) may be 
dependent of the body needs of certain hematopoietic lineages (Kehrer 2009; Miharada et 
al. 2005; Miharada et al. 2008).  
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In contrast with the pro-apoptotic evidence, LCN2 was also described as a survival 
factor. The findings of Tong et al. (2005) include normal proliferation of A549 cells that 
were over expressing LCN2 and an increase in the apoptotic effect of celecoxib-related 
compounds in cells that were silenced for the lipocalin by small-interfering RNA (siRNA). 
Also, the high expression of LCN2 in various cancers, in normal mammary glands, uterus 
and testis is concomitant with a survival function (Kehrer 2009). 
1.2.3.3. LCN2 in neoplasia 
LCN2 is found highly expressed in diverse types of human cancer such as ovarian, 
breast, colorectal and lung cancer. The biological significance of this expression is not 
clear, with the protein promoting different effects in different types of cancer. For instance, 
LCN2 was found to restrain the invasive and metastatic phenotypes in colon cancer cells 
(Lee et al. 2006). Conversely, LCN2 appears to facilitate the regeneration of the 
gastrointestinal mucosa through promotion of cellular migration (Playford et al. 2006). 
Furthermore, LCN2 is linked with the invasive potential of breast cancer (Leng et al. 
2009). 
1.2.3.4. LCN2 in thermal stress 
An unexpected role for LCN2 in thermal protection of the cell was recently 
described by Roudkenar et al. (2009). In this work, CHO and HEK293T cells that were 
transfected with lipocalin 2 presented higher proliferative rates after a cold stress, when 
compared with controls. The number of apoptotic cells and the expression of pro-apoptotic 
proteins were also lower in the transfected cells. Accordingly, A549 cells that were 
silenced via siRNA for the LCN2 gene were more prone to apoptosis. An increase in the 
expression of the protein in the liver, heart and kidney of mice that were subjected to 
thermal stress was also noticed. Overall, these results suggest a cytoprotective role for 
LCN2 against cold stress, a function that might be useful for the reduction of cold 
associated damage in the storing of organs for transplantation (Roudkenar et al. 2009). 
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1.3. Our work: goals and methodologies 
The biological importance of LCN2 is far from fully understood. To our 
knowledge, important and/or precise functions of the protein in physiological conditions 
remain unclear. LCN2 expression has been reported in diverse tissues, under various 
conditions, in varied animals species and strains. Hence, to our knowledge, a coherent and 
exhaustive description of the ontogenic expression profile of LCN2 in a single biological 
system in either physiological or inflammatory conditions does not exist.  
The aim of this work is to determine the LCN2 expression pattern (mainly by 
immunohistochemical analysis) in mice during fetal development, early stages of adult 
growth and in later ages (by analyzing specific organs such as liver, spleen, thymus and 
brain) under physiological/control (saline injection) and acute inflammatory conditions 
(24h after LPS administration).  With this description, we expect to contribute to the 
characterization of the role of LCN2 in the innate immune system response and in iron 
delivery. 
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2 
Experimental Procedures 
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2.1. Animals and treatments  
All animal experiments followed the European Community Council Directive 
86/09/EEC guidelines for the care and handling of laboratory animals. The C57BL/6 mice 
(Charles River, Barcelona, Spain) were maintained in a 12-h light/dark cycle at 22.5 °C 
and 55% humidity and fed with regular rodent chow (Mucedola, Milano, Italy) and tap 
water ad libitum.  
For this study C57BL/6 mice embryos from developmental stages E11,5, E13,5, 
E15,5, E17,5 and E19,5 were used. Pregnant progenitors were intraperitoneally injected 
with either control solution (0.9% NaCl) or with 5 µg/g body weight of LPS (Escherichia 
coli, serotype O26:B6; Sigma, St Louis, USA). We have previously shown that this LPS 
dosage induces acute inflammatory response in mice (Marques et al. 2008; Marques et al. 
2009). Twenty four hours later animals were anesthetized, transcardially perfused with 
saline and embryos harvested into 4% PFA in PBS. For the analysis of LCN2 expression 
pattern in post natal animals only male mice were used. The analyzed ages were 3, 7, 16, 
21, 30, 60, 120, 365 days. The injections procedure was the same as described above. After 
anesthetized and transcardially perfused with saline, organ samples (brain, liver, thymus, 
spleen and kidney) were collected and fixed in 4%PFA in PBS for 5 days. For each 
condition at least 3 animal samples were used. 
2.2. Immunohistochemistry 
After fixation, embryos and organ samples were embebed in paraffin and sectioned 
(4 µm) for immunohistochemistry. All staining steps were performed at room temperature. 
Briefly, tissue sections were deparaffinized in xylol and ethanol, rehydrated and 
microwave heated for 20 minutes with citrate buffer (Thermo) for antigen retrieval 
Samples were washed in PBS and endogenous peroxidase activity was quenched in 0.3% 
H2O2 in PBS for 30 minutes. Samples were rinsed with PBS and blocked with 0,4% bovine 
serum albumin in 0,3% triton PBS (0,3% PBS-T) for 1 hour. Sections were afterwards 
incubated with goat anti-mouse LCN2 (R&D Systems, Minneapolis, MN, USA) overnight. 
Samples were washed with PBS-T and incubated with biotinylated anti-goat secondary 
antibody (Vector Laboratories Inc., Burlingame, CA, USA) at a 1:200 dilution for an hour 
and afterwards incubated with avidin-biotin immunoperoxidase reagent (Vectastain Elite 
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diaminobenzidine (DAB; Sigma Immunochemicals, St. Louis, USA) dissolved in Tris-
HCl/H2O2. Samples were counterstained with hematoxylin and when necessary were 
stained with periodic acid-Schiff reagent (PAS). Negative controls included incubation 
with 0,4% BSA in PBS-T  without the primary antibody. 
Given the high number of samples to be analyzed, we had to repeat this protocol 
multiple times. To ensure comparable results through all the samples, we tried to ensure 
identical conditions in each time the protocol was executed.  
2.3. Immunofluorescence 
For immunofluorescence experiments, a slightly modified protocol was used. No 
endogenous peroxidase quenching was necessary. A custom made rabbit anti-mouse TTR 
antibody (Sousa et al. 2007) was used at dilution of 1:1000. We used the following 
secondary antibodies at a 1:500 dilution: donkey anti-goat Alexa Fluor 488, donkey anti-
goat Alexa Fluor 594 and donkey anti-rabbit Alexa Fluor 594 (Molecular Probes, Carlsbad, 
CA, USA). Sections were mounted with ImmuMount mounting medium (Thermo). In 
some samples we added DAPI (Thermo) at a 1:2000 dilution, which stains the cell nuclei, 
to the mounting medium. 
2.4. Image acquisition and statistical analysis  
The samples were examined under optical (BX61; Olympus, Hamburg, Germany) 
or confocal (FV1000; Olympus, Hamburg, Germany) microscopes. To quantify the 
differences in terms of LCN2 expressing cells in the liver of some animals, series of 5 
micrographs per animal (n=3 animals per condition, with the exception of some embryo 
time points/mother injection) covering an area of 0.149 mm
2
 each were taken and cells 
were counted. We did the same for the spleen, with the micrographs (covering an area of 
0.0367 mm
2
 each) being taken in the red pulp area of the organ. LCN2 positive cell 
numbers are reported as mean ± s.e. and statistical differences were assessed using 
standard two tailed Student t test, with differences considered significant at p<0.05. 
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Results 
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In this study we characterize the ontogenic expression profile of LCN2 in mice, 
under physiological conditions and after an acute inflammatory stimulus. As described in 
detail in the materials and methods section, embryos and target tissue samples were 
collected 24 hours after injection of either saline or LPS, fixed in formalin and embedded 
in paraffin. Tissue sections were then analyzed after LCN2 immunohistochemistry and/or 
immunofluorescence. A detailed description of the LCN2 expression pattern for each 
sample analyzed follows. An overview of the expression pattern of the protein can be 
found in Table 1.  
3.1. LCN2 expression pattern in the liver 
The expression of LCN2 was first detected in the liver of control animals at the 
embryonic age 11,5 (E11,5) (Figure 4). As can be observed in Figure 4.A, during 
embryonic development the number of LCN2-positive cells markedly increased in the liver 
of control embryos (whose progenitor was injected with vehicle). We extended this 
qualitative observation by counting the number of LCN2 positive cells and confirmed that 
cells that present LCN2 positive signal increase with embryonic age (Figure 4.B). Some of 
the immunoreactive cells presented a nucleus with a multilobulated shape that is 
characteristic of neutrophils (Figure 5.A, 5.B). No hepatocyte appears to be stained. Of 
notice, LCN2 positive cell count in embryos whose progenitors were injected with LPS is 
slightly inferior to the control counterparts, although the difference is not statistically 
significant (Figure 4.B). Importantly, we failed to obtain viable embryos of embryonic age 
E11,5 and 19,5 from pregnant mice that were injected with LPS. It has been reported that 
pregnant females of some mice strains, C57BL/6 included, are susceptible to the effects of 
inflammatory agents such as LPS. The intraperitoneal administration of LPS in early stages 
of pregnancy can result in the resorption of the embryos, while the same stimulus in later 
gestational periods can lead to abortion (Xu et al. 2007; Role and Labor 2006; Robertson et 
al. 2007). This might explain the failure to obtain viable embryos from females that were 
injected with LPS. 
After birth, animals that were injected with saline presented a significant number of 
LCN2-positive cells which persisted until P7 (Figure 6). From P16 onwards, LCN2 
positive cells were rarely observed in the liver of control animals (Figures 6 and 7). 
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Identical to what was observed in embryonic samples, we detected neutrophil like cells in 
the liver of control newborn animals (Figure 5.A, 5.B). Furthermore, no hepatocytes 
appear to be stained. Structures typical of the developing organ such as erythroblastic 
islands were observed, but no LCN2 signal appears to be associated with them (Figure 
5.A). Erythroblastic islands were no longer seen from P16 onwards. 
The intra-peritoneal administration of LPS induced a ubiquitous LCN2 expression 
in the liver of all post-natal animals (Figure 6 and 7). The intensity of the signal through 
the different ages did not altered significantly, with all hepatocytes presenting LCN2 
immunoreactivity. Besides hepatocytes, LCN2 immunoreactivity was also observed in 
neutrophil-like cells which were present in higher number when compared to control 
animals (Figure 4.B). We did not observed LCN2 staining in Kupffer-like cells in any of 
the LPS injected subjects (Figure 5.A).  
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Figure 4   Immunohistochemistry for LCN2 in embryos and analysis of the number of LCN2 stained cells in the 
liver of liver of mice of embryonic and post natal time points. No viable embryos were obtained for the E11,5 and 
E19,5 time points of lipopolysaccharide (LPS) injected females. (A) (Upper panel) LCN2 staining cells in the liver of 
embryos whose progenitor was injected with saline increase in number throughout embryonic development. (A) (Lower 
panel) LPS administration in pregnant mice dams does not result in a evident change in the pattern of LCN2 stained 
cells, when compared with control animals. (B) Quantification of LCN2 stained cells in the liver reveals that the number 
of positive cells increases with age until E19,5. This increase is similar in embryos derived from LPS or saline injected 
pregnant females; nevertheless, LPS treated subjects display a lower number of LCN2 positive cells when compared with 
controls, although the difference is not statistical significant. After birth, the number of LCN2 expressing cells in saline 
injected animals decreases to residual numbers from P16 onwards. LPS administration results in a statistical significant 
increase, when compared to controls, in LCN2 positive cells in the liver, with the exception occurring in P7 animals. 
Given that LPS injection results in LCN2 signal in the hepatocytes, only non-hepatocyte cells that stained for LCN2 were 
counted. The trend in cell counts between control and LPS injected animals in P120 subjects is also noticed in the 
remaining post-natal time points. Series of 5 images per subject were taken in the liver parenchyma, covering an area of 
0.149 mm2. For each condition the liver of 3 animals was analyzed, with the exception of the 13,5 and 15,5 embryos 
from LPS injected females (n=1). Scale bar = (A) 100 µm.  
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Figure 5  Identification of LCN2 expressing cells in the liver of control and LPS injected mice. (A) LCN2 
immunoreactivity increases in the liver after LPS injection, when compared with the control counterparts. The exception 
occurs at embryonic stages. (A) (Upper Panel) LCN2 is not detected in hepatocytes (arrow) of saline injected animals in 
any of the studied age. Erythroblastic islands-like structures (star) are present in the liver until P7, and no LCN2 
immunoreactivity in these cell clusters was observed. Some of the LCN2 positive cells have neutrophil like morphology, 
as can be seen in the insets. (A) (Lower Panel) The cell types that express LCN2 in the fetal livers of LPS injected 
pregnant dams is identical to what we observed in controls. On the other hand, LPS injection in post-natal animals results 
in overall LCN2 expression in the hepatocytes (arrow). As observed in saline treated animals, erythroblastic islands-like 
structures (star) are present and do not express LCN2. Neutrophil like cells displaying LCN2 immunoreactivity were also 
observed (P3, inset). Kupffer-like cells do not display LCN2 immunoreactivity (inset in P60 animal). (B) 
Immunofluorescence for LCN2 (Red) and the nuclear marker DAPI (Blue) confirm the presence of neutrophil like cells 
(arrowhead).  Scale bar = (A) 20; (B) 50 µm.  
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Figure 6  Immunodetection of LCN2 in the liver of post natal animals that were injected with saline or LPS. Only 
animals from pre-weaning ages P3 to P21 are shown. While LCN2 staining is evident in P3, it diminishes with age and 
from P16 onwards is rarely detected (A, C, E, G). On the other hand, LPS administration results in a broad LCN2 
distribution in all analyzed ages (B, D, F, H). Scale bar = (A - H) 100 µm. 
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Figure 7  Immunodetection of LCN2 in the liver of adult animals that were injected with saline or LPS. Only 
animals from P30 to P365 time points are shown. No consistent LCN2 signal is detected in the liver of saline injected 
mice (A, C, E, G). As observed in younger animals, LPS injection leads to a ubiquitous expression of LCN2 in the liver 
of mice at least till one year of age (B, D, F, H). Scale bar = (A - H) 200 µm. 
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3.2. LCN2 expression pattern in the brain  
During embryonic development, occasional staining for LCN2 was observed in the 
fetal brain but it was restricted to the stromal space of the CP in mice whose progenitor 
was injected with either saline or LPS (Figure 8.A).  
In post natal animals injected with saline LCN2 expression in the brain was 
restricted to the CP stroma of 3 day old subjects. The older animals did not present any 
LCN2 signal in the brain (Figures 9 and 10). On the other hand, the peripheral 
inflammatory stimulus in post natal animals resulted in LCN2 immunoreactivity localized 
in the CP epithelia and stroma, blood vessels of the brain parenchyma and ependyma cell 
layer (Figure 8.B-E). This pattern was consistent in all of the post natal ages studied 
(Figures 9 and 10), with the notable exception of P3 animals, were no LCN2 signal was 
detected in CP epithelial cells (Figure 11.A). Immunofluorescence colocalization of LCN2 
and transthyretin, a protein expressed specifically by the epithelial cells of the CP, further 
confirms that LCN2 is not expressed by the CP epithelial cells of 3 days old pups that were 
injected with LPS, while in older animals colocalization is evident in the CP epithelia 
(Figure 11.B-D). 
Interestingly, the occurrence of the protein in LPS injected animals is 
heterogeneous through the epithelial cells layer of the CP, since not all cells present LCN2 
signal. This pattern was seen in all of the post-natal time points from P7 onwards (Figure 9 
and 10). We did not observed a clear age-dependent pattern in terms of LCN2 positive CP 
epithelial cells.  
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Figure 8  LCN2 immunoreactivity in the brain of control and LPS animals. LCN2 staining was restricted to the CP, 
ependymal layer lining the ventricles and blood vessels. (A) Occasional LCN2 staining was observed in the stromal space 
of some of the E17.5 embryos whose progenitor was injected with saline. Identical pattern occurred in some of the 
embryonic samples of other time points/injection. (B) In LPS injected mice endothelial cells of the blood vessels present 
in the brain parenchyma also stained for LCN2. (C) In older animals endothelial LCN2 signal was also observed. This 
pattern of expression was consistent through all of the studied post-natal time points. (D) LCN2 immunoreactivity was 
detected in ependymal cells (arrow) of 3 day old animals injected with LPS. (E) Similar to (D), LPS injection in year old 
animals results in occasional staining in cells of the ependyma layer (arrow). This pattern of LCN2 presence in the 
ependyma was observed in all post-natal time points. Scale bar = (A) 100; (B, C) 50 µm. 
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Figure 9  Immunohistochemistry for LCN2 in the choroid plexus of LPS and saline injected animals. Only animals 
from P3 to P21 are shown. The injection of LPS results in the presence of LCN2 staining in CP epithelial cells (arrow) 
from 7 day old animals onwards (B, D, F, H). Staining in the stromal area of the CP (arrowhead) occurs in all LPS injected 
animals. No LCN2 immunoreactivity is detected in saline controls (A, C, E, G). Scale bar = (A-H) 100 µm. 
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Figure 10  Immunodetection of LCN2 in the choroid plexus of LPS injected and saline animals. Only animals 
from P30 to P365 are shown. No staining for LCN2 is visible in control animals (A, C, E, G). LPS administration 
results in LCN2 detection in epithelial cells (arrow) and in stroma cells of the choroid plexus (arrowhead) (B, D, F, H). 
Scale bar = (A-H) 200 µm.  
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Figure 11  LCN2 localization in the Choroid Plexus of LPS injected animals. (A) Immunohistochemistry for LCN2 
demonstrates that in P3 animals the protein signal is restricted to the stromal space (arrow). From P7 onwards, LCN2 is 
also present in the epithelial cells of the CP (arrowhead). (B, C and D) Immunofluorescence against LCN2 (C) and 
transthyretin (TTR), a protein produced only by CP epithelial cells (B), confirms that the expression of LCN2 in CP 
epithelial cells (arrowhead) of LPS injected animals only occurs from P7 onwards, as the merging of (B) and (C) reveals 
(D). Scale bar = (A-D) ?????? 
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3.3.  LCN2 expression pattern in the spleen 
The study of the expression pattern of LCN2 in the spleen was confined to the post-
gestational period since this organ was not observed in all embryos analyzed. In the post-
natal spleen the expression of LCN2 was detected in all analyzed ages in both saline 
(control) and LPS treated animals.  
In the spleen of post-natal control animals the presence of LCN2 was mainly 
restricted to cells in the red pulp region. This expression pattern was generally consistent 
throughout age (Figures 12 and 13), although the intensity of LCN2 positive staining in P3 
animals was slightly weaker than the one observed in older control animals. LCN2 positive 
cells in the white pulp area were rarely observed. It is important to notice that a clear 
histological distinction of the white pulp from the surrounding tissue was not possible in 
the P3 and P7 animals. Thus we did not characterize the LCN2 expression profile in the 
white pulp of those specimens.  
The LPS injection resulted in a notable increase of LCN2 positive cell number in 
the red pulp area of the spleen, when compared with the same area of saline injected 
animals. This observation is consistent for all of the post-natal time points analyzed (Figure 
12 and 13). The analysis of the number of LCN2 positive cells in the red pulp region of 
animals of different ages confirmed that this increase in LCN2 positive cells after the 
inflammatory stimulus occurs independently of the animal age since LCN2-positive cells 
numbers are identical through the different ages (Figure 14). Similarly, the cell numbers of 
control animals do not present significant differences between the different ages. The 
inflammatory stimulus also resulted in a higher occurrence of LCN2 stained cells in the 
white pulp area of the spleen when compared with controls, despite the low number of 
positive cells in this region of the spleen. This pattern was consistent in all studied time 
points (with the exception of P3 and P7 subjects for the reasons referred above), although 
we only depict the P60 time point in Figure 15.   
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Figure 12  Immunodetection of LCN2 in the spleen of saline and LPS injected animals. Only animals from P3 to 
P21 are shown. In control animals LCN2 positive cells are present in the red pulp area (arrowhead), with the staining 
in the white pulp area being practically absent (A, C, E, G). The LPS inflammatory stimuli result in the increase of 
LCN2 positive cells in the red pulp area of the organ (arrowhead) (B, D, F, H). Occasional LCN2 positive cells are 
also present in higher number in the white pulp area of the spleen of LPS injected animals (arrow in H). Scale bar = 
(A-H) 200 µm. 
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Figure 13  Immunohistochemistry for LCN2 in the spleen of saline and LPS injected animals. Only animals from 
P30 to P365 are shown. Identically to what was observed in younger animals, saline injection results in the detection of 
some LCN2 positive cells, namely in the red pulp area (arrowhead in G) of the organ, with staining in the white pulp 
(arrow in G) area being practically non-existent  (A, C, E, G). LPS administration results in an overall increase in the 
number of LCN2 positive cells, both in the red pulp area (arrowhead in H) and in the white pulp area (arrow in H) of 
the organ (B, D, F, H). Scale bar = (A-H) 500 µm. 
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Figure 14  Number of LCN2 positive cells in the spleen of animals of different ages. In saline injected animals the 
cell number does not change significantly with age. LPS administration results in a significant increase in the number of 
LCN2 immunoreactive cells when compared with controls but there is no significant variation between animals of the 
LPS-injected group. Series of 5micrographs per subject were taken in the organ red pulp, with each photo covering an 
area of 0.0367 mm2. For each condition the spleen of 3 animals was analyzed. 
Figure 15  Localization of LCN2 immunoreactivity in the spleen of 60 days old animal injected with either LPS 
or saline. (A) In control animals LCN2 staining in the white pulp (WP) is practically non-existent, while in the red pulp 
region (RP) cells positive for the protein are found scattered. (B) LPS administration results in a notorious increase of 
LCN2 stained cells in the red pulp area (RP) of the organ. Some cells that stain for LCN2 (arrow) are present in the 
splenic white pulp (WP). This pattern of expression is consistent through all of the studied post-natal time points. Scale 
bar = (A,B) 200 µm. 
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3.4. LCN2 expression pattern in the kidney 
LCN2 presence in the kidney was first detected in late embryonic development, 
more specifically from E17,5 onwards. The protein appears to be localized in tubular 
structures (Figure 16), whilst the glomeruli do not present LCN2 immunoreactivity. To 
identify with more precision the structures that present LCN2 positive signal, we 
counterstained the slides with periodic acid-Schiff (PAS). PAS is a histological technique 
that stains complex carbohydrates in magenta. In the kidney, PAS stains mainly the 
basement membrane which supports the tubular epithelium and the brush border that 
projects into the lumen of proximal tubules (PT). This staining technique is useful for a 
clearer distinction between proximal and distal tubules (DT), since DT do not possess 
brush border, thus they do not present the typical magenta staining in the apical side of the 
tubules. Counterstaining with PAS revealed that the LCN2 staining in the kidney of E17,5 
embryos from saline injected females appears to occur mainly in PT (Figure 16.A3). Of 
notice, not all of the PT display LCN2 signal. This pattern of expression persists in post 
natal animals injected with saline (Figure 17 and 18), although from P16 onwards the 
LCN2 immunostaining in these structures is usually very faint (Figure 16.C3). 
Interestingly, whereas in the embryo and newborn kidney this LCN2 staining is distributed 
in the cytoplasm of PT cells, from P16 onwards the staining is localized at the apical site of 
the tubules (Figure 16.A2, 16.C3). Furthermore, little to no LCN2 immunoreactivity was 
detected in the nephrogenic zone (NZ) of the newborn animals, either P3 or P7. The NZ, 
where nephron differentiation occurs, is visible at the periphery of the organ and structures 
typical of the area such as ureteric buds are visible (Figure 16.B1). 
LPS administration resulted in a clear and strong immunoreactivity in the kidney of 
all post-natal animals (Figure 17 and 18). In LPS injected newborn mice the LCN2 signal 
intensity and presence was higher when compared with the respective controls (saline 
injected newborns). Of interest, the tubular structures that display LCN2 expression are the 
same both in LPS and saline injected newborns. 
LCN2 signal was present in the cortical area of all of the post-natal time points of 
LPS injected animals. The cells expressing LCN2 belong mainly to PT-like structures 
(Figure 16.C2, 16.D2). Furthermore, the expression appeared to occur with more intensity 
in the apical side of the PT (Figure 16.C1, 16.D1). Of notice, similarly to what was 
described for control animals, not all of the PT presented LCN2 staining. Immunoreactivity 
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in PT that is continuous with the renal corpuscle was sporadically observed (Figure 
16.D1). Interestingly, from P60 onwards LCN2 staining also appeared in the medullar 
portion of the organ, mainly in collecting ducts-like structures. Furthermore, the incidence 
of LCN2 stained structures in the medulla increased with age (Figure 18). Hence, while in 
the two month old animals the LCN2 signal is scattered through the medulla, in P120 
subjects a significant proportion of the filtrate collecting structures are LCN2 positive and 
in P365 animals most of the medullar area displays LCN2 immunoreactivity (Figure 
16.D3). Simultaneously, the frequency of cortical DT that exhibits LCN2 staining 
increases from P60 onwards, with the majority of the DT of P365 animals presenting 
LCN2 immunoreactivity (Figure 16.D2).  
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Figure 16  Morphological analysis of kidney LCN2 expression. The animals/images presented are representative of 
the main LCN2 staining trends observed in the kidney. (A1) LCN2 signal was found scattered in the kidney of E17,5 
mice whose progenitor was injected with saline. (A2) Higher magnification of (A1) shows specific LCN2 staining in 
proximal tubules (PT)-like structures. No staining is detected in the glomeruli (G). (A3) Counterstaining with PAS 
confirms that LCN2 staining occurs in the PT, which presents magenta toned apical brush borders. (B1) LCN2 signal is 
restricted to the cortical area of the kidney in 3 day old pups injected with saline. No LCN2 stain is observed in the 
nephrogenic zone (NZ) of the organ, where structures that will develop into the mature nephron are recognizable, such as 
the ureteric bud (UB). (B2) Magnification of A1 suggests that the LCN2 stained cells are part of the PT. (B3) (C1) LPS 
injection results in the LCN2 immunostaining in PT like structures. (C2) Counterstaining with PAS confirms the 
+previous observations. Of notice, LCN2 presence is concentrated in the apical side of the PT. No LCN2 
immunoreactivity is observed in distal tubules (DT). (C3) Cortical magnification of a saline injected kidney, 
counterstained with PAS. Faint LCN2 signal is observed in some PT structures (star). (D1) Similarly to C1, LPS 
administration resulted in an apical LCN2 signal in PT-like structures. A weak LCN2 immunoreactivity is visible in the 
PT that is continuous with the glomeruli (G). (D2) Counterstaining with PAS confirmed the previous observations. Of 
notice, distal tubules (DT) also display LCN2 signal. (D3) Medullar portion of the organ counterstained with PAS. The 
majority of collecting ducts-like structures present LCN2 immunostaining. Scale bar = (A1) 500; (B1, D1) 100; (A2, A3, 
B2, B3, C1-D2) 50; (D3) 100 µm.  
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Figure 17  Immunohistochemistry for LCN2 in the kidney of LPS and saline injected mice. Only animals 
from P3 to P21 are shown. In the control animals LCN2 presence was mainly detected in the cortex of P3 and P7 
subjects (A, C). From P16 onwards faint LCN2 signal is detected in the cortex of saline injected subjects (E, G). 
LPS administration results in an overall increase of LCN2 positive cells in the cortical area of the organ (B, D, F, 
H). Scale bar = (A ? F) 200; (G, H) 500 µm. 
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Figure 18  Immunodetection of LCN2 in the kidney of LPS and saline injected mice. Only animals from P30 to 
P365 are shown. In saline injected animals faint LCN2 expression is detected in the cortical area of the kidney (A, C, 
E, G). LPS injection leads to a significant LCN2 immunoreactivity (B, D, F, H), namely in the cortical area of the 
organ. In older animals, the majority of cells of the medullar portion are LCN2 positive (F, H). Scale bar = (A-H) 
500 µm. 
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3.5. LCN2 expression pattern in the thymus 
 Of all of the organs analyzed for the presence of LCN2, the thymus appeared to be 
the most unaffected by the inflammatory stimulus. LPS administration did not appear to 
alter the pattern of expression of LCN2 in the thymus when compared with the saline 
counterparts (Figure 19 and 20). The presence of LCN2 stained cells was observed from 
the first post natal time point (P3) onwards, in both LPS and saline injected mice. In P3 
animals the number of LCN2 positive cells was scarce. The number of LCN2 positive cells 
increased slightly in P7 animals to then appear more frequently in the animals with ages 
from P16 to P60. In older animals, P120 and P365, the distribution of the LCN2 positive 
cells was reduced. Interestingly, in all analyzed time points the LCN2 positive cells were 
present both in the medulla and cortex of the organ.  
It is known that the thymus atrophies with age, with the thymic tissue being 
replaced by fat (Savino 2000; Sutherland et al. 2005). We had difficulties in obtaining 
structurally well conserved thymus from the one year old animals, and while we were able 
to find a consistent pattern of LCN2 expression in the organ of saline injected P365 
animals, the same was not true for the LPS counterparts. Different patterns of LCN2 
expression were observed in the thymus of these P365 LPS injected animals, ranging from 
residual to frequent LCN2 staining of the thymic cells. Hence, the analysis of LCN2 
expression in this particular time point and injection is not conclusive. Nevertheless, in 
Figure 20.H a micrograph representative of the observed organs can be observed, with 
scattered LCN2 staining in the medulla and cortex of the organ.  
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Figure 19  Immunodetection of LCN2 in thymus of saline and LPS injected mice. Only animals from P3 to P21 are 
shown. No difference in the distribution of LCN2 positive cells between LPS and control counterparts is observed. The 
LCN2 stained cells are scarce in P3 (A, B), their number increase in P7 (C, D) and are found scattered in P16 and P21 (E 
- H). The distribution of the immunoreactive cells appears identical between the cortex and the medulla of the organ. 
Scale bar = (A - D) 200; (E ? H) 500 µm. 
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Figure 20  Immunohistochemistry for LCN2 in the thymus of saline and LPS injected mice. Only animals from 
P30 to P365 are shown. No evident difference in the distribution of LCN2 positive cells between LPS and control 
counterparts. Some LCN2 positive cells are found scattered in P30 and P60 subjects (A - D), but identically distributed 
between the cortex and the medulla of the organ. A reduction in LCN2 stained cells is noticed from P120 onwards (E ? 
G). (H) Although there was not a clear pattern of LCN2 presence in the P365 animals injected with LPS. Scale bar = (A 
- F) 500; (G, H) 200 µm.  
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3.6. LCN2 expression profile summary 
Bellow we present an overview of the LCN2 expression pattern in the studied 
tissues of all post-natal animals.  
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In this study we characterize the ontogenic expression pattern of LCN2, a 25 kDa 
lipocalin protein, under physiological and acute inflammatory conditions (24 hours after a 
single bacterial lipopolysaccharide (LPS) injection). LPS is a constituent of the cell wall of 
Gram-negative bacteria that is capable to elicit acute inflammatory responses. Multiple 
molecules are modulated during the inflammatory response and there is a growing body of 
evidence that supports the participation of LCN2 in that response (Alpízar-Alpízar et al. 
2009; Berger et al. 2006; Flo et al. 2004; Marques et al. 2008; Sunil et al. 2007). 
We analyzed by immunohistochemistry the expression pattern of LCN2 at several 
embryonic time points (E11,5; E13,5; E15,5; E17,5; E19,5) and at various post-natal time 
points until adulthood (namely in the brain, liver, spleen, kidney, and thymus), both in 
physiological and inflammatory conditions. There are various reports that identify LCN2 
expression in diverse tissues, under various conditions, in varied animals species and 
strains. However, it does not exist, to the best of our knowledge, a consistent description of 
the expression profile of the protein trough the mammal life span, under standardized 
conditions, either in physiological or inflammatory scenarios.  
Hence, with this work we aim to contribute to a deeper knowledge of LCN2 
presence and distribution through the mice lifetime, both in basal and in acute 
inflammatory conditions. Furthermore, with the construction of this expression profile we 
expect to contribute to a better understanding of the biological relevance of LCN2, namely 
in iron distribution and innate immunity.  
Our work demonstrates that LCN2 expression is present but varies through mice 
lifetime, from early embryonic stages to adulthood. Furthermore, we show that LCN2 
expression is highly dependent of the physiological state. We will next discuss in further 
detail the LCN2 expression pattern we described with this study. Since the LCN2 signal in 
the embryonic phase was concentrated in the fetal liver and kidney, we will address the 
pattern of expression of both fetal organs in the discussion of the corresponding tissue.  
4.1. LCN2 in the developing liver 
The liver was one of the embryonic organs where we detected a significant LCN2 
presence. LCN2 was first detected in the liver of control E11,5 animals and from this time 
point the number of liver LCN2 positive cells increased significantly trough embryonic 
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development. After birth, the number of LCN2 positive cells significantly decreased in 
control mice and from P16 onwards, the presence of LCN2 positive cells in the liver was 
practically nonexistent. A subset of the observed LCN2 expressing cells displayed 
neutrophil like morphology. The presence of granulocytes in the fetal liver is not 
surprising, as the organ is the main site of blood cells formation during fetal development. 
The production of blood cellular components, a process commonly designated by 
hematopoiesis, is a relatively well described phenomena and in the developing mouse is 
first observed in the extra-embryonic yolk sac around embryonic day 7,5 (E7,5). 
Hematopoiesis then occurs in a sequence of intraembryonic sites that include the aorta-
gonad-mesonephros region, thymus, placenta, fetal liver, spleen and bone marrow (for 
review see Cumano and Godin (2007)). The fetal liver is seeded at around E11,5 with 
hematopoietic stem cells (HSC), the precursors of all blood cell lineages (Mikkola and 
Orkin 2006). The organ then becomes the major site of hematopoiesis until birth, when the 
bone marrow replaces it as the main site of the hematopoietic process (Orkin and Zon 
2008).  
The micro environment of the fetal liver favors the rapid expansion of the HSC and 
hematopoietic progenitor cells, along with the differentiation of erythrocytes, myeloid 
cells, and lymphocytes (Cumano and Godin 2007; Orelio et al. 2009; Tada et al. 2006). 
The hematopoietic activity in the mouse fetal liver reaches its peak between E14,5 and 
E16,5 to then decrease until it ceases shortly after birth. Accordingly, the cellular density 
of some of the blood cells differentiated in this organ decreases gradually until early days 
after birth (Ema and Nakauchi 2000; Huang et al. 2007; Sasaki and Sonoda 2000; Tada et 
al. 2006; Wolber et al. 2002). In this sense, the pattern of LCN2 cellular expression that we 
observed in the liver of control perinatal animals is roughly in accordance with the cellular 
expansion derived from the hematopoietic process in this organ. To the best of our 
knowledge there is no concrete data evidencing LCN2 presence in hematopoietic cells of 
the fetal liver. There are, however, some reports that describe LCN2 expression in different 
lineages of hematopoietic cells in other hematopoietic sites. For instance, Miharada et al.( 
2005) demonstrate the presence of LCN2 mRNA and protein in granuloid and erythroid 
progenitor cells isolated from the bone marrow of adult mice. Although at lower levels, 
they also detected LCN2 mRNA in immature hematopoietic progenitors (Miharada et al. 
2005). These authors later reported LCN2 mRNA expression in monocyte/macrophage 
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lineage cells, granulocytic cells, erythroid cells and HSC isolated from human umbilical 
cord blood. They also demonstrated LCN2 expression at the protein level in granulocytic 
cells (Miharada et al. 2008). Taking this data in consideration it is plausible that, in 
addition to neutrophils, some of the herein reported cells expressing LCN2 in the liver of 
embryos and newborn mice might belong to different hematopoietic lineages that are found 
to develop in the organ. Interestingly, Miharada et al. (2005) also reported that incubation 
of mouse hematopoietic cells with LCN2 resulted in reduced monocyte/macrophage 
???????? ??????????????? ????? ????? ?????????? ?????????? ????????????? ???????????????? ????
survival (Miharada et al. 2005). Identical influence of LCN2 in human erythroid and 
monocyte/macrophage lineages was reported later by Miharada et al. (2008). Other authors 
also describe LCN2 as a facilitator of hematopoietic cells apoptosis (Devireddy et al. 2001; 
Lin et al. 2005). These results suggest a possible role for LCN2 in the modulation of the 
hematopoietic process. Indeed, Miharada et al. (2008) theorizes that in physiological 
conditions, the serum levels of LCN2 might be sufficient to inhibit to some extent the 
survival/ proliferation of hematopoietic lineages such as erythroid and macrophages. 
However, in scenarios where additional hematopoiesis is required, it is possible that those 
progenitor cells become less susceptible to the LCN2 pro apoptotic effects, eventually due 
to increased expression of intracellular survival factors (Kehrer 2009; Miharada et al. 
2008). 
In apparent contrast with these observations, LCN2 deficient mice do not present a 
perceptible imbalance of blood cellular components (Berger et al. 2006; Flo et al. 2004), 
with some authors suggesting that in the absence of LCN2, alternative proteins may ensure 
the maintenance of adequate hematopoietic cell numbers (Miharada et al. 2005). Whether 
this putative LCN2 mediated control of hematopoiesis occurs in the fetal liver during 
embryonic development is unknown. 
Our data suggest that the observed LCN2 expression in the liver of control embryo 
and newborn animals may be linked with the hematopoietic process. Despite that, it is most 
likely that not all of the LCN2 positive cells are of the hematopoietic type. Indeed, we 
report here that the numbers of LCN2 positive cells in the liver during the perinatal period 
increase until E19,5. Considering that the peak of the hematopoietic activity in the liver of 
mice is described as to occur between 14,5 and 16,5 days of pregnancy (Ema and Nakauchi 
2000; Tada et al. 2006), it is unlikely that the herein reported increase in numbers of LCN2 
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positive cells in the final stages of pregnancy are exclusively derived of the hematopoietic 
process.  
The above discussion regarding the LCN2 expression in the fetal liver was focused 
in the results obtained from embryos of saline injected females. We had difficulties in 
obtaining viable dams from LPS injected females, as many of the embryos were either 
aborted or resorpted. Indeed, we were not able to retrieve a single embryo of E11,5 and 
E19,5 from LPS injected females. Negative effects of LPS in developmental outcome has 
already been described  (Role and Labor 2006; Xu et al. 2007). TNF-??????????????????????
in response to LPS, appears to be a major mediator of fetal loss (Robertson et al. 2007). 
Regardless the low rate of success in embryo recovery from LPS injected females, we were 
able to obtain embryos for the embryonic time points E13,5, E15,5 and E17,5. LCN2 
expression pattern in those embryos was similar to the observed in control animals. LCN2 
positive cell numbers are slightly lower in the liver of embryos from LPS injected females 
when compared with the control counterparts. The nature of those LCN2 expressing cells 
is likely similar to the described above for control embryos. 
The effect of the mother LPS injection in the embryo LCN2 expression is unknown. 
It is known that LPS administration induces LCN2 expression in post natal animals. In 
embryos of LPS injected females we did not observed major differences in terms of LCN2 
signal distribution when comparing to the control embryos, suggesting that the protein 
expression was not triggered by LPS. Interestingly, there is evidence that maternally-
administered LPS can induce inflammatory response in the embryo, in organs such as the 
liver and brain (Ning et al. 2008) (for review see Wang et al. (2006)). Whether LPS can 
reach the embryo itself is still unclear (Li et al. 2008). Diverse studies suggest that the 
inflammatory molecules that are present in embryos after maternal LPS administration are 
transferred from the mother into the embryo, rather than being produced by the embryo 
itself (Ning et al. 2008; Wang et al. 2006). Given all this data, it would be plausible to 
expect that maternal LPS injection would induce a visible increased LCN2 presence in the 
embryo. However, as reported herein, that was not the case.  
We also report that embryos from LPS injected females presented slightly lower 
LCN2 positive cell counts in the liver, when compared with the liver of control embryos. 
As discussed above, it is likely that some of those LCN2 expressing cells are of the 
hematopoietic type. If we assume that 1) some of those LCN2 expressing cells are indeed 
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hematopoietic, 2) LCN2 that is expressed by the mother in response to LPS might reach 
the embryo and 3) LCN2 can exert pro apoptotic effects in some hematopoietic lineages in 
the fetal liver, identical to what happens in other hematopoietic sites (Miharada et al. 2005; 
Miharada et al. 2008), it is then tempting to hypothesize that this additional LCN2 
(resultant from the LPS administration) might decrease the proliferation of some 
hematopoietic lineages in the fetal liver, thus resulting in lower numbers of putative 
hematopoietic LCN2 expressing cells. 
Clearly more research is required in order to understand the role of LCN2 in the 
embryo in the context of progenitor inflammatory scenarios. Further work is also required 
in order to identify with more accuracy the cell types that express LCN2 in the liver of 
developing and newborn mice. Without this description, the biological significance of 
these findings remains highly elusive. 
4.2. LCN2 in the post-natal liver 
As referred above, in control (saline injected) post-natal animals LCN2 expression 
in the liver decreased in the first week of the newborn life. From P16 onwards, LCN2 
positive cells were rarely seen in the liver and they normally exhibited neutrophil like 
morphology. On the other hand, 24 hours after the intra-peritoneal injection of LPS in post-
natal mice a strong LCN2 immunostaining occurred in the liver, in an expression pattern 
identical between all time points analyzed. As referred above, LPS is a well known 
inflammatory inducer. The endotoxin recognition by mammalian cells occurs mainly by 
the cell surface tool-like receptor 4 (TLR4). The interaction between LPS and TLR4 results 
in the activation of the receptor which triggers signaling cascades in the cells that 
ultimately promotes the activation of immune response against the inflammatory stimulus 
(Freudenberg et al. 2008). While this TLR4 mediated response to inflammatory signals has 
been mainly associated and described in immune cells such as granulocytes and 
macrophages, growing evidence suggests that tissue cells, hepatocytes included, can also 
react to inflammatory stimulus through TLR4 mediated pathways (Liu et al. 2002; Parker 
et al. 2007). 
LCN2 synthesis in response to inflammatory stimulus (including LPS), has been 
described (Cowland et al. 2003; Flo et al. 2004; Marques et al. 2008; Sommer et al. 2009; 
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Sunil et al. 2007). We report herein that in LPS injected post-natal animals the majority of 
the hepatocytes are LCN2 positive, a result consistent with previous reports where hepatic 
LCN2 expression was ubiquitously detected after an acute inflammatory stimulus (Flo et 
al. 2004). In fact, hepatocytes are responsible for the synthesis of many of the acute phase 
proteins that regulate inflammatory responses to infection or tissue injury (Tilg et al. 
1997). LCN2 expression in mice liver after LPS administration has been reported as time-
dependent, with the peak synthesis occurring between 4 and 24 hours post-injection, with 
the protein expression returning to basal levels 48 hours after endotoxins injection 
(Marques et al. 2008; Sunil et al. 2007). In addition to hepatocytes, we also observed a 
significant presence of neutrophil like cells (with the characteristic multilobulated shaped 
nuclei) stained for LCN2 in the liver of LPS injected mice of all of the studied time points. 
The increased presence of neutrophils in the liver after LPS injection is not surprising as 
tissue neutrophil mobilization and infiltration is one of the key features of mammalian 
immune response to inflammatory stimulus (Nussler et al. 1999).  
As suggested by previous reports (Meheus et al. 1993; Sunil et al. 2007; Zhang et 
al. 2008)   we expected to find LCN2 staining in the hepatic resident macrophages, also 
known as Kupffer cells, in animals that were injected with LPS. However, we did not 
found LCN2 positive Kupffer cells in any of the analyzed post-natal animals. Kupffer cells 
are pivotal to the innate immune response to acute endotoxemia, as they eliminate gram-
negative pathogens and LPS from the liver and systemic circulation (Ojaniemi et al. 2006). 
They are also responsible for the production of inflammatory mediators such as IL-1, IL-6 
and TNF-???????????chemokines that potentiate the recruitment of inflammatory cells to the 
infected organ (Ramaiah and Jaeschke 2007). To date the demonstration of LPS-induced 
expression of LCN2 in liver macrophages is restricted to the study of Sunil et al. (2007). 
These authors reported LCN2 mRNA and protein expression in Kupffer cell extracts 
isolated from the liver of rats treated with LPS. These results contrast with our 
observations. We cannot discard the possibility that LCN2 expression in Kupffer cells is 
not strong enough to be detected by the immunohistochemistry technique we used. On the 
other hand it must be noticed that the Kupffer cells isolation protocol used by (Sunil et al. 
2007) did not result in completely pure cellular extracts (purity above 90%), therefore the 
????????????????????????????????????????????? ???????????????????? ???????????????? ??? ????
expression results provided by Sunil et al. (2007) must not be completely discarded. 
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The precise mechanism(s) by which LCN2 is modulated in the liver in response to 
inflammation are not fully understood. LPS administration stimulates synthesis of diverse 
cytokines. Some cytokines, such as IL-??? ???? ??-?? has been reported to induce LCN2 
expression in different cell types (Bando et al. 2007; Cowland et al. 2006). However, 
whether if such cytokines are able to elicit LCN2 synthesis at the hepatocyte level remains, 
to the best of our knowledge, unknown. On the other hand, there is evidence that LCN2 
induction by LPS in different tissues (liver included) is TLR4 mediated (Flo et al. 2004; 
Sunil et al. 2007), thus indicating that a direct interaction between the pathogens and TLR4 
may be required to trigger LCN2 synthesis in those tissues. 
Also unclear is the biological relevance of this ubiquitous response to LPS by the 
liver. Some authors hypothesize that the synthesized LCN2 may down regulate 
inflammatory signals to prevent extended hepatic damage originated from the 
inflammatory response (Sunil et al. 2007). Alternatively, or in addition, LCN2 appears to 
contribute to the organism immune response through a bacteriostatic mechanism. As 
previously noticed, it has been reported that the liver synthesizes LCN2 shortly after an 
endotoxic stimulus. Serum levels of LCN2 are also greatly up-regulated (Flo et al. 2004; 
Sunil et al. 2007). LCN2 was found to compete with bacteria for the organism iron 
resources, thus exerting a bacteriostatic effect (Berger et al. 2006; Flo et al. 2004). Indeed, 
these authors demonstrated that bacteria-induced liver burden and mortality rates are 
higher in LCN2 knockout mice than in wild type counterparts. This bacteriostatic capacity 
of the protein strongly suggests that LCN2 contributes to the innate immune response 
through an iron depletion mechanism that prevents the proliferation of invading pathogens 
(Berger et al. 2006; Flo et al. 2004).  Being the liver a main site of LCN2 induction in 
inflammatory scenarios (Flo et al. 2004), it appears possible that this hepatic produced 
LCN2 plays a key role in the organism response to peripheral inflammation.  
Considering that our studies demonstrate a consistent pattern of LCN2 expression 
in the liver of LPS injected mice through all of the post natal time points, it is likely that 
the molecular mechanisms by which LCN2 is induced in this organ and the role of the 
protein in the acute immune response (and other functions as well) may be similar during 
the animal lifetime. 
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4.3. LCN2 in the developing kidney 
Our study demonstrate that in addition to the liver, LCN2 positive 
immunoreactivity is present in the kidney of late embryos and newborn animals, an 
observation that suggests that the protein may be involved in the development of this 
organ.  
The organogenesis of the kidney is a relatively complex but well described process. 
The formation of the definitive nephron depends on inductive interactions between two 
different tissue precursors, the ureteric bud (UB) that forms the collecting ducts, and the 
metanephric mesenchyme (MM), which differentiates into the glomeruli and renal tubules. 
In mouse, the UB elongates and penetrates into the MM at around E10,5. The UB then 
branches and MM cells aggregate at the UB tips. Afterwards, these cells undergo 
mesenchyme to epithelial conversion, forming renal vesicles, while the remaining 
mesenchyma cells form the interstitial stroma. Two consecutive clefts transform the renal 
vesicle into an s-shaped body. The distal end of this structure later fuses with the UB to 
form a continuous epithelial tubule. The differentiation of the glomerular structures occurs 
in the proximal end of the s-shaped body after the invasion of the proximal cleft by 
endothelial cells. The nephron differentiation occurs in a centrifugal fashion, with the 
oldest nephron localized closer to the medulla and the immature ones being present in the 
nephrogenic zone (NZ) in the outer cortex of the organ. UB ramification and nephron 
maturation in the NZ ceases in the first days of the animal life (for review see Shaw et al. 
(2009) and Dressler (2006)) 
 The participation of LCN2 in the kidney development was first described by Yang 
et al. (2002). These authors demonstrated that LCN2 is one of the factors produced by UB 
cells that promote the conversion of immature MM into renal epithelial cells. The data 
presented suggested that this inductive action of LCN2 may be resultant of the delivery of 
iron by the protein into the early epithelial progenitors (Yang et al. 2002). Furthermore, 
they also reported in vivo LCN2 expression in rat UB, but not in mesenchymal cells. In 
addition to the mesenchyma-to-epithelia inductive effect, in vitro studies indicate that 
LCN2 also participate in the structural organization of the renal epithelia (Gwira et al. 
2005). In contrast with the findings of Yang et al. (2002), we did not found LCN2 signal in 
the UB cells of any of the embryonic and newborn kidneys. The utilization of different 
rodent species and different methodological approaches may explain this discrepancy. 
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However, we detected LCN2 immunoreactivity in structures morphologically similar to PT 
in perinatal control animals. The LCN2 staining was strongly present in the cortical area of 
these animals until P7. The biological significance of these findings is not clear. Our 
observations suggest that LCN2 could be locally expressed by the proximal tubular 
epithelia and/or captured from the same tubules after glomerular filtration. Importantly, 
most of the existing data, which is resultant from studies with mature kidneys, indicates 
that rather from being locally expressed, LCN2 in the PT results from the rescue of the 
protein from the glomerular filtrate (Kuwabara et al. 2009; Mori et al. 2005; Schmidt-Ott et 
al. 2006; Schmidt-Ott et al. 2007). Furthermore, the protein was found to deliver iron into 
the PT (Mori et al. 2005; Schmidt-Ott et al. 2007). We will approach this LCN2 mediated 
delivery of iron in the kidney with further detail later in the discussion. Whether this 
recapture of LCN2 from the glomerular filtrate and consequent deliver of iron to the PT 
cells occurs in the perinatal kidney is currently unknown. However, since the blood of 
these animals contains a significant amount of non-transferrin-bound iron (NTBI) (Yang et 
al. 2003), it is tempting to hypothesize that LCN2 may in fact represent a pathway of 
relevance in the recapture and delivery of iron into the PT of the perinatal animals. As 
transferrin bound iron becomes the predominant form of circulating iron in older subjects 
(Smith and Thévenod 2009), LCN2 may lose importance to other iron related proteins such 
as transferrin in kidney iron reabsorption. To further clarify if LCN2 is locally synthesized 
or captured from the circulating pool of the protein, it would be of interest to assess the 
LCN2 mRNA content in the PT of the perinatal animals by in situ hybridization, for 
instance. Also, it would be of relevance to determine the PT expression levels of the 
putative LCN2 receptors, 24p3R and megalin. This clarification of the LCN2 origin could 
partially unveil the putative function of the protein in the setting of the perinatal kidney. 
Hence, if the protein is captured by the PT after glomeruli filtration, presumably delivering 
iron into the cells, one may consider that LCN2 contributes for the maintenance of the PT 
cell iron pool. In addition of being used in PT cells metabolic processes, this iron could 
also be exported into the bloodstream, either by FPN or by LCN2 itself (Schmidt-Ott et al. 
2007; Devireddy et al. 2005). If, on the other hand, LCN2 is being produced by the PT 
cells, it is plausible to hypothesize that if the protein is secreted to the extra-cellular space, 
it could promote the nephron differentiation effects described above. The possibility of 
LCN2 recovery in the PT cells and consequent export of the protein to the kidney 
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parenchyma, where it could exert the referred nephron differentiation effects cannot be 
ruled out. Clearly further work is necessary in order to understand the origin and biological 
importance of LCN2 in the developing kidney. 
4.4. LCN2 in the post-natal kidney 
 We also report here that from P16 onwards a weak LCN2 staining is present in the 
kidney of control animals, namely in the apical side of some PT structures. There is some 
contradictory data regarding the basal LCN2 expression profile in this organ. In rat, Friedl 
et al. (1999) report LCN2 expression in the distal portions of the organ, whereas Rached et 
al. (2008) depict it at the renal PT.  Roudkenar et al. (2009) did not found any LCN2 signal 
in the organ of normal animals. In human normal kidneys, LCN2 immunoreactivity was 
observed by Friedl et al. (1999) and Ding et al. (2007) in the PT of the organ. On the other 
hand, Mori et al. (2005) demonstrates that LCN2 signal is instead present in the distal 
tubules and in the medullar collecting ducts of human kidney. Mishra et al. (2003) reported 
weak LCN2 expression in the kidney of normal mouse, an observation that is concomitant 
with the results herein reported for saline animals from P16 onwards.  
 Regardless the inconsistency of the existing data in terms of LCN2 expression in 
the kidney of normal subjects, the biological relevance of the protein in this context 
remains unclear. The work of Mori et al. (2005) was essential for a better understanding of 
the potential role of LCN2 in the kidney. These authors demonstrated in vivo that tagged 
LCN2 is quickly recaptured by the PT of the nephron after glomerular filtration. 
Furthermore, through injection with 
55
Fe-loaded LCN2 they proved that the protein can 
deliver iron into PT cells (Mori et al. 2005). The authors also propose that the endogenous 
LCN2 may exert identical functions. It is then plausible to consider that the herein reported 
LCN2 presence in the kidney of control animals from P16 onwards might be resultant from 
the protein recapture from the glomerular filtrate. Furthermore, the protein staining in these 
kidney samples was very faint, suggesting low rates of the protein uptake from the filtrate. 
This observation is concomitant with the low levels of serum LCN2 in healthy individuals 
(Jiang et al. 2008; Flo et al. 2004; Mori et al. 2005).  
 Iron recovery by the kidney from the glomerular filtrate appears to rely on multiple 
pathways, with the most well described ones being mediated by DMT1 and transferrin 
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(Smith and Thévenod 2009). The current data indicate that despite the apparent limited 
relevance, LCN2 may constitute another mechanism of iron recuperation from the 
glomerular filtrate, thus contributing to the body iron homeostasis; the extent of LCN2 
participation in these processes needs to be further clarified. Interestingly, the iron delivery 
capabilities of LCN2 in the kidney appear to gain special importance in kidney disease 
conditions, as it will be next discussed.  
 Etiologies such as kidney transplantation and cardiac cirurgy can result in acute 
kidney injury (AKI) (Di Grande et al. 2009). Sepsis can also result in AKI. Indeed, 
depending on the septic severity, up to 51% of septic patients present AKI. Furthermore, 
the mortality rates are higher in septic patients that develop AKI than in patients with AKI 
alone (Schrier and Wang 2004). As an model of gram-negative sepsis, LPS administration 
is capable of inducing renal dysfunction and injury (Cunningham et al. 2002; Cunningham 
et al. 2004; Guo et al. 2004; Heemskerk et al. 2006; Langenberg et al. 2008; Yura et al. 
2009). The pathophysiology of sepsis-induced AKI is complex and far from fully 
understood (Wan et al. 2008). Nevertheless, an increasing body of evidence indicates that 
diverse mechanisms may participate in this condition. These include alterations in systemic 
and renal hemodynamics, renal cell damaging mediated by systemic and/or locally 
produced inflammatory cytokines such as TNF-????????????????????????????????stress (Wan 
et al. 2008; Wang et al. 2005; Wu et al. 2007; Zager et al. 2006; Zhang et al. 2000). 
Diverse studies report that increased levels of LCN2 in the serum and urine observed after 
diverse etiologies such as renal transplant and sepsis correlates significantly with the 
development of kidney damage (Mishra et al. 2006; Mori et al. 2005; Wheeler et al. 2008). 
This up-regulation of the protein is strong and fast, supporting LCN2 as a sensible and 
predictive biomarker of AKI (Di Grande et al. 2009).  
 We report herein that the intraperitoneal administration of LPS resulted in a strong 
LCN2 signal in the kidney of all post-natal animals. In all time points, a significant portion 
of the cortical PT was stained for LCN2. Interestingly, our results are consistent with 
studies that report renal LCN2 expression in diverse AKI scenarios (Devarajan 2008; 
Kuwabara et al. 2009; Mishra et al. 2006; Mori et al. 2005). It must be noticed that we did 
not evaluated the damage levels of the renal structures in any sample. The serum levels of 
LCN2 rise greatly in inflammatory situations (Flo et al. 2004; Marques et al. 2008), with 
the liver presumably being one of the main sources of the protein (Flo et al. 2004). 
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Interestingly, much of the observed LCN2 staining in the kidney PT was concentrated in 
the apical side of the tubular structure, suggesting that the protein may be recaptured in the 
PT. This observation is consistent with previous reports that demonstrate that LCN2 can be 
reabsorbed by PT cells from the glomerular filtrate (Kuwabara et al. 2009; Mori et al. 
2005; Schmidt-Ott et al. 2007). As previously discussed, exogenous LCN2 can also deliver 
iron into the PT cells, as reported by Mori et al. (2005). These authors further demonstrated 
that this delivery of iron-loaded LCN2 leads to up regulation of Hox1 and maintenance of 
N-cadherin, both proteins that favor cellular viability (Mori et al. 2005). Indeed, 
administration of LCN2 before or after ischemic-injury can minimize kidney damage 
(Mishra et al. 2004; Mori et al. 2005). It is therefore possible that if the observed LCN2 in 
the PT of LPS injected animals results from glomerular filtrate recapture, the protein may 
be contributing for the maintenance of cellular viability of the tubular structures, thus 
protecting the renal tubules from possible damage.  
 In addition to the LCN2 staining observed in the PT, we also report that LPS 
injection results in LCN2 immunoreactivity in the kidney DT and collecting ducts. 
Interestingly, this pattern of immunoreactivity was only visible from two month old 
animals onwards, since in younger animals neither DT nor collecting ducts presented the 
protein signal. The observed staining in the distal portion of the nephron in older animals is 
consistent with the reported increase of the protein in the same structures in AKI scenarios 
of rodent and humans (Kuwabara et al. 2009; Mishra et al. 2006; Schmidt-Ott et al. 2006). 
Evidence indicates that the LCN2 synthesized in the distal sections of the kidney in AKI 
settings is released into the urine (Schmidt-Ott et al. 2007). It has been hypothesized that 
this secreted LCN2 could promote an anti-bacterial effect in the lower urinary tract 
(Schmidt-Ott et al. 2007). In addition, as the distal segments are also damaged in AKI, 
some authors consider that the expressed LCN2 may also favor the survival of the distal 
cells, although no clear evidence supporting this hypothesis exists (Devarajan 2008; 
Devarajan 2010).  
 The mechanism of LCN2 induction in the distal nephron by LPS is currently 
unclear. As part of the innate immune response to LPS, the systemic levels of 
inflammatory mediators such as TNF-????????-????????????????????????????????????????????
recognition by systemic TLR4 (Cohen 2002; El-Achkar et al. 2008; Ramesh et al. 2007; 
Tracz et al. 2007). Since IL-??????????????????????????????????????????????????????(Cowland 
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et al. 2006), it is plausible to speculate that LCN2 expression in kidney tubules may be 
induced by such mediators. Interestingly, recent studies report that a direct endotoxin-
kidney cells interaction may also contribute to the renal response to inflammatory stimulus 
(Cunningham et al. 2004; El-Achkar et al. 2008). Indeed, TLR4 is found present in most of 
the rat kidney, with both mRNA and protein expression being reported in the distal portion 
of the nephron (El-Achkar et al. 2008). Similarly, TLR4 mRNA is found present in the 
distal nephron of mice (Wolfs et al. 2002). Kidney TLR4 expression increases after septic 
stimulus (El-Achkar et al. 2006). Furthermore, injected endotoxin can access the renal 
tubules, including sections of the distal nephron (El-Achkar et al. 2006). Taking these data 
in consideration, we might consider that the observed LCN2 signal in the DT and medulla 
may be a consequence, at least partially, of local TLR4 activation by LPS. It is noteworthy 
that while PT cells present TLR4 and endotoxin can access those cells (El-Achkar et al. 
2008), there is not, to the best of our knowledge, evidence that LCN2 expression is 
triggered in these cells. Instead, the protein presence in the PT cells appears to be 
correlated with absorption of the protein from the glomerular filtrate, as described above. 
 In addition to the action of inflammatory mediators and/or endotoxin stimulus, it is 
possible that the herein described presence of LCN2 in the distal nephron occurs in 
response to a possible undergoing epithelial stress and/or damage. Indeed, LCN2 
expression is significantly induced in damaged epithelial cells of organs such as liver, lung 
and colon (Devarajan 2008; Devarajan 2010; Wheeler et al. 2008). Concomitantly, LCN2 
is expressed by damaged renal epithelia in diverse renal diseases and conditions 
(Kuwabara et al. 2009). However, it must be noticed that while LPS has been reported to 
induce AKI (as discussed before), most of the histological findings describe damage only 
in the proximal components of the nephron. Indeed, to the best of our knowledge, there is 
no histological data demonstrating LPS-induced damage in the distal nephron. 
 We report herein that LPS administration results in an evident increase of LCN2 
expression in the kidney of the analyzed post-natal animals. Interestingly, the pattern of the 
renal LCN2 distribution was not homogenous trough age. Indeed, we observed a lack of 
LCN2 signal in the distal portion of the nephron in young mice injected with LPS, with the 
protein immunoreactivity, which first appears in this renal area in the two month old 
animals, being ubiquitously present in the DT and medulla of older animals. The cellular 
and/or molecular mechanisms behind this striking difference and corresponding biological 
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relevance are unknown. Some reports suggest that kidney susceptibility to diverse kidney-
damaging substances, endotoxin included, appears to be dependent of the 
age/developmental phase of the organ, with younger kidneys being less affected by the 
damaging stimulus than older counterparts. Various factors may be accountable for these 
age-related differences. Of special importance appears to be the functional maturity of the 
kidney. It is known that the kidney morphological differentiation achieves completion 
shortly after birth. At this period, however, the organ is far from being fully functional. In 
rodents, the functional maturation of the kidney develops quickly in the post-natal period. 
The levels of various renal transporters increase significantly in the first weeks of the 
animal life (Suzuki 2009). Concomitantly, the renal blood flow (RBF) and glomerular 
filtration rate (GFR) are found to increase in the first weeks of life in the rat (Horster 1977; 
Solhaug et al. 2004; Suzuki 2009). Some authors suggest that this reduced RBF and GFR 
observed in younger animals may result in reduced renal damage in AKI scenarios 
(Solhaug et al. 2004). Indeed, low GFR is thought to be behind the lower glomerular 
changes observed in younger rats injected with gram-negative Salmonella enteritidis when 
compared with older counterparts (Hurley et al. 1989; Solhaug et al. 2004). Lower RBF in 
younger animals is accountable for the reduced aminoglycosides-induced renal damage 
when compared with adult animals (Cowan et al. 1980; Solhaug et al. 2004). Concomitant 
with these findings, cisplatin-induced AKI is more evident in older rodents than in young 
ones (Ali et al. 2008; Appenroth et al. 1988; Espandiari et al. 2009; Fleck et al. 2001).  
 In addition to kidney hemodynamics, other factors may contribute for the reduced 
levels of renal damage in younger animals. For instance, Zager et al. (2008) observed that 
as LPS-induced AKI increases with age, the basal levels of renal cortical cholesterol, a 
molecule that exerts protective effects in the kidney cells, actually decreases through the 
same period, thus indicating that cholesterol may be one of the contributing factors for the 
different age-related sensibilities of the kidney to the endotoxin effects. The authors further 
hypothesize that age-dependent fluctuation in the expression of other molecules such as 
growth factors and Hox1 may also contribute for this effect (Zager et al. 2008). Taking all 
this data in consideration, it appears evident that the kidney response to some damaging 
stimulus is dependent of the developmental stage of the organ and that multiple 
mechanisms may be behind this phenomenon. Considering that LCN2 signal in the distal 
portion of the kidney appears to reflect underlying cell damage (Kuwabara et al. 2009), it 
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is tempting to speculate that the herein reported lack of LCN2 signal in the distal nephron 
of young mice might reflect reduced/ absent damage in those cells. This (putative) reduced 
damage in the kidney of younger animals might be attributed to the factors discussed 
above.  
 In summary, our results demonstrate that an acute inflammatory stimulus induces a 
strong LCN2 presence in mice kidney tubules. The distribution of the protein signal was 
age-dependent, with the kidney of older animals displaying LCN2 immunoreactivity 
trough all of the nephron. Whereas the biological significance of this expression pattern is 
unclear, it is possible that it is linked to acute renal damage. LCN2, possibly trough iron 
delivery, may promote the survival of renal PT cells, thus limiting renal damage. 
Furthermore, LCN2 expression by the distal nephron (which presumably occurs in 
response to local epithelial damage) might exert a bacteriostatic effect in the lower urinary 
tract. The absence of LCN2 signal in the distal nephron of younger animals might reflect a 
lower susceptibility of those structures to renal damage. It would be of interest to assess the 
histological damage in the various portions of the nephron and try to correlate it with 
LCN2 immunoreactivity. Further work is required in order to better understand the 
biological significance of renal LCN2 presence in the context of acute phase response to 
inflammatory stimulus.  
 
4.5. LCN2 in the brain 
LCN2 presence in the embryonary brains, either from saline or LPS injected 
progenitors, was limited to occasional staining in the stromal space of the choroid plexus 
(CP). Identical staining pattern was observed in newborn (P3) saline injected animals. 
These LCN2-expressing cells are likely to be circulating cells such as neutrophils. In older 
saline injected animals no LCN2 expression was visible in the brain. On the other hand, 
LPS peripheral administration in post natal animals resulted in evident LCN2 expression in 
different areas of the brain, namely in the CP epithelia and stroma, ependyma and 
endothelial cells of the blood vessels. This pattern was consistent in all post-natal animals 
injected with LPS with the notable exception of 3 day-old pups, were no LCN2 signal was 
observed in the epithelial cells of the CP, despite the protein expression in the CP stroma, 
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ependyma and blood vessels. The CP consists of a network of capillaries surrounded by a 
monolayer of epithelial cells that is located within the brain ventricles, being the epithelial 
layer responsible for the production of most of the cerebrospinal fluid (CSF) present in the 
brain (Speake et al. 2001). Whereas CP capillaries are fenestrated, the epithelial cells 
junctions are tight, thus limiting the passage of substances and cells through the cell layer 
into the CSF. For this reason, CP is part of the blood-CSF barrier (Redzic and Segal 2004). 
In addition to CSF synthesis and restriction of molecular/cellular passage from blood to 
CSF, the CP produces molecules that are important for the regular CNS functioning, such 
as growth factors and hormones (Skipor and Thiery 2008). Interestingly, the CP also has 
receptors for most of these molecules, suggesting an autocrine and/or paracrine modulation 
of CP functioning (Chodobski and Szmydynger-Chodobska 2001).  
Increasing evidence suggests that the CP may have an important role in the immune 
response to inflammatory stimulus in the CNS. For instance, the main receptor of LPS, 
TLR4, is expressed in physiological conditions in rodents CP (Laflamme and Rivest 2001; 
Chakravarty and Herkenham 2005)??????????????? ?????????????????????????????????????
IL-1 and IL-6 were found up-regulated after inflammatory stimulus in the CP epithelial 
cells and CSF (Chakravarty and Herkenham 2005; Marques et al. 2007; Marques et al. 
2009; Nadeau and Rivest 1999; Quan et al. 1999). Marques et al also reported higher levels 
of LCN2 expression in the CP and CSF of LPS challenged mice (Marques et al. 2008). In 
accordance with this study by Marques et al, we demonstrate here that LPS administration 
clearly induced LCN2 immunostaining in the CP epithelial cells, stromal cells and blood 
vessels of the studied post-natal time points, with the exception of P3 old animals.  
The mechanisms behind the induction of LCN2 synthesis in the CP by LPS are 
unclear. Identical to what we discussed before, it is possible that certain cytokines may 
trigger LCN2 synthesis in the CP after an inflammatory stimulus. Concomitantly, IL-???
receptor is expressed by the CP (Cunningham et al. 1992). It is also possible that LPS 
induced LCN2 expression in the CP is TLR4 mediated (Marques et al. 2008). The herein 
reported absence of LCN2 expression in the CP epithelia of LPS injected P3 animals 
suggests an impaired response of the CP in terms of LCN2 synthesis to the peripheral 
inflammatory stimulus in those animals. The reason for this apparent lack of response to 
LPS is unclear. It is known that newborns are more susceptible to infections, presumably 
due to incomplete maturation of both adaptative and innate immune systems (Belderbos et 
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al. 2009). Interestingly, diverse studies report that TLR mediated response to inflammatory 
stimulus (such as LPS) is impaired in blood cells of neonatal subjects, with the expression 
levels of cytokines such as TNF- ?????-6 and interleukin-12 being lower in newborn blood 
cells that were treated with LPS, when compared with older counterparts (Belderbos et al. 
2009; Chelvarajan et al. 2004; Levy et al. 2004; Wit et al. 2003). Concomitantly, TLR4 
mediated activation of NF-kB, a key transcriptional factor for expression of cytokines, is 
found depressed in neonatal monocytes and macrophages (Maródi 2006). Maródi suggests 
that this apparent impairment of TLR signaling pathways and consequent diminution of the 
inflammatory response may be, at least partially, responsible for the deficient innate 
immunity of newborns. Given these data, it may be hypothesized that the lack of LCN2 
expression in the CP epithelia of P3 animals injected with LPS might be a result of 
impairment of TLR4 signaling. Furthermore, it must be noticed that TLR4 expression itself 
can be tissue and age dependent (Harju et al. 2001). The profiling of TLR4 expression in 
the CP of newborn animals has not been reported, despite the description of TLR4 mRNA 
presence in the brain of 7 days old rats (Eklind et al. 2001). In addition, the sensitivity to 
LPS can be dependent of the levels of TRL4 expression (Bihl et al. 2003). Therefore, it is 
plausible to hypothesize that the absent LCN2 expression in the CP epithelia of P3 animals 
may be a consequence of: 1) decreased functionality of TLR4 signaling and/or 2) low 
expression of TLR4 in the newborn CP. 
Taking into account the described bacteriostatic capacity of LCN2 and the reported 
presence of the protein in both CP and CSF after LPS challenge, it is possible that LCN2 
may be important to restrict bacterial penetration and proliferation in the CSF, thus 
representing a significant element of the innate immune protection of the CNS (Marques et 
al. 2008). Our work suggests that while this putative innate immune mechanism is present 
trough the animal lifespan, it may be somehow compromised in newborn animals.  
Interestingly, in addition to LCN2, other iron-related genes were found altered in the CP 
and CSF after a peripheral inflammatory stimulus. Indeed, Marques, Falcao, et al. (2009) 
report an increase in the expression of genes encoding for hepcidin and ferritin in the CP 
shortly after LPS injection. They also observed an increase in hepcidin prohormone in the 
CSF. These observations led the authors to hypothesize that in response to the 
inflammatory stimulus, the CP may increase its iron storage capacity and at the same time 
reduce the export of iron into the CSF, thus promoting decreased iron availability in the 
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CSF (Marques, Falcao, et al. 2009). Since LCN2 is also synthesized by the CP and 
secreted into the CSF, it appears likely that this protein may also contribute for the 
alteration of the CSF iron status, thus ultimately participating in the modulation of iron 
homeostasis in the brain (Marques et al. 2008; Marques et al. 2009). Our results suggest 
that this contribution of LCN2 to the regulation of CSF iron homeostasis in acute phase 
scenarios may be consistent through age, with the exception of the first 3 day old animals, 
as we did not detected LCN2 signal in the CP epithelial cells of those animals.   
We report here for the first time LCN2 presence in cells of the ependyma layer. 
Immunoreactivity was detected in all post-natal animals that were injected with LPS. The 
biological relevance of ependymal LCN2 presence is unknown. The ependyma layer lines 
the ventricular cavity of the central nervous system and is formed by a simple layer of 
epithelial cells (ependymal cells). Most of this ependymal cells present microvilli and cilia. 
The ependyma constitutes a barrier between CSF and brain extracellular fluid. The cilia 
present in ependyma cells beat in a coordinated fashion, suggesting that the layer may 
promote the CSF movement through the ventricles (Del Bigio 2010). Ependyma may 
regulate the transport of diverse substances between CSF and the brain (Bruni 1998; 
Hauwel et al. 2005). It is then likely that the ependyma may protect the brain from 
hazardous metabolites present in the CSF (Del Bigio 1995; Kuchler et al. 1994). 
Furthermore, ependyma also responds to inflammatory stimulus through cytokines 
expression (Hauwel et al. 2005; Xia et al. 2006), suggesting that it might act as a first line 
of defense against infection in the brain (Del Bigio 2010). This cytokine expression is 
possibly TLR mediated, with TLR4 being present in physiological conditions in the 
ependyma (Chakravarty and Herkenham 2005).In addition, the protein is upregulated after 
LPS challenge (Xia et al. 2006). We report here LCN2 presence in some cells of the 
ependyma layer of LPS injected animals. Whether LCN2 is expressed by the ependyma 
itself or is absorbed by the CSF is unclear. The observation that in P3 LPS injected animals 
LCN2 signal is present in the ependyma but not in the epithelia CP supports the LCN2 
expression by the ependyma hypothesis. How LCN2 is induced in the ependyma and its 
biological function needs to be clarified.  
Further studies are required in order to better understand the role LCN2 in cerebral 
immunity and iron homeostasis, in particular in newborns. It would be of interest to 
determine with more accuracy the onset of LPS-induced LCN2 expression in the CP. Also, 
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the measurement of CP TLR4 levels and associated inflammatory mediators in the 
newborn subjects could allow a better understanding of the molecular mechanisms 
responsible for the herein reported differences in terms of CP LCN2 expression between 
LPS injected newborn and older animals. 
4.6. LCN2 in the spleen 
The profile of LCN2 expression in the spleen of post-natal animals did not change 
significantly through age. In control animals the staining was restricted to some cells of the 
red pulp area of the organ. We have not identified the cell types that present LCN2 
expression. Flo et al. (2004) reported that in the red pulp area of spleen of C57BL/6 control 
mice only neutrophils displayed LCN2 signal. It is then likely that most of the herein 
observed LCN2 expressing cells in that splenic area are indeed neutrophils. 
LPS injection resulted in an increase in the presence of LCN2 positive cells in the 
spleen in all studied time points, mainly in the red pulp area. Although we did not identify 
the remaining populations of LCN2 expressing cells, it is likely that they are of identical 
nature as reported by Flo et al. (2004). These authors described an induction of LCN2 
expression in red pulp macrophages, fibroblasts and endothelial cells in E. coli injected 
C57BL/6 mouse (Flo et al. 2004). Furthermore, we report here a slight increase in the 
occurrence of LCN2 stained cells in the white pulp of the organ, an observation similar to 
the reported by Flo et al. (2004). Accordingly to these authors, the LCN2 expressing cells 
in the white pulp presented morphologic characteristics of macrophages and dendritic cells, 
thus it is likely that the herein reported white pulp LCN2 positive cells are of the same 
type.  
The biological relevance of this expression pattern is, to the best of our knowledge, 
unknown. It is known that in addition to the liver, the spleen is a primary site to LPS 
response (Smolinski and Pestka 2005). Splenic macrophages display phagocytic activity 
towards the endotoxin, thus contributing to its elimination from the bloodstream (Feleder 
and Blatteis 2006). In addition, the activation of splenic macrophages and other splenic 
cells such as dendritic cells by the endotoxic stimulus results in the prompt production of 
inflammatory mediators by those cells (Randolf et al. 2009; Smolinski and Pestka 2005; 
Tracey 2007). Indeed, the spleen is an important site of inflammatory cytokine synthesis 
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during inflammation scenarios, with the organ being the main producer of systemic TNF 
(Huston et al. 2006; Smolinski and Pestka 2005), further demonstrating that this organ 
plays a role in the immune response to inflammatory agents.  
While the liver appears to be an important source of LCN2 following an 
inflammatory stimulus (Flo et al. 2004), the precise contribution of the spleen to the 
systemic levels of LCN2 in such scenarios is unknown. Given the (above discussed) 
contribution of the spleen to inflammatory mediators production, the response of the organ 
in terms of LCN2 immunoreactivity to an E.coli challenge and the significant increase of 
serum LCN2 after the bacterial stimulus (Flo et al. 2004), it is possible that the spleen can 
also be a source of systemic LCN2.  
We report here that LPS (which is a major component of gram-negative cell wall) 
administration induces increased splenic LCN2 immunoreactivity in all of the post-natal 
animals in an identical pattern, suggesting that the mechanisms by which the protein is 
induced and the biological relevance may be similar through age. Further studies are 
necessary in order to better understand the relevance of splenic LCN2, both locally and 
systematically, to the organism response to an inflammatory stimulus.  
4.7. LCN2 in the thymus 
We report herein the presence of LCN2 stained cells in the thymus of all post-natal 
time points. For each analyzed age we did not found significant differences in the pattern 
of LCN2 expression between control and LPS animals. We observed more LCN2 stained 
cells in the thymus of animals ranging from P16 to P60, with the cells being identically 
scattered between the organ medulla and cortex. We did not identify the nature of these 
LCN2 expressing cells. While LCN2 presence in the thymus was previously reported 
(Berger et al. 2006; Cowland and Borregaard 1997; Devireddy et al. 2001; Miharada et al. 
2005), the immunohistochemical description of the protein in this organ is restricted to the 
work of Friedl et al. (1999). These authors depict LCN2 signal in both human and rat 
Hassal???? ???????????? ?????? ???? ??????????? ??????????? ???????? ??? ???? ??????? ?????????
Furthermore, they also describe LCN2 expression in other epithelial cells of the medulla of 
rat thymus. It is possible that some of the herein reported signal of LCN2 in the thymus is 
originated by these particular structures. Interestingly, Friedl et al. (1999) do not describe 
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LCN2 expression in either rat or human thymic cortex, an observation that contradicts our 
results. Although the organ histology is found conserved between diverse species (Haley 
2003), the thymic LCN2 expression pattern might be, to some extent, species-dependent. 
As mentioned above, LCN2 presence in the thymus has already been described. 
The protein relevance in the organ functioning, however, is currently unknown. The 
thymus is the principal site of T-lymphocytes (T cells) formation in mammals. T cells are 
key mediators of adaptive immune response and their maturation from immature 
thymocytes is a highly regulated process that occurs in various discrete steps. Diverse 
molecules present in the thymic niche modulate the thymocyte maturation processes (Hale 
and Fink 2009; Savino et al. 2007). Interestingly, Devireddy et al. (2001) suggests that 
LCN2 might also participate in such processes. These researchers observed that LCN2 
primary thymocytes incubated with LCN2 display higher levels of apoptosis. Furthermore, 
they reported that primary thymocytes incubated with dexamethasone, a synthetic 
glucocorticoid that is known to induce apoptosis in thymocytes (Walker et al. 1991), 
synthesize LCN2. These results lead to the hypothesis that LCN2 may be involved in 
thymocyte selection processes (Devireddy et al. 2001). In contrast with these results, 
Berger et al. (2006) reported that LCN2 deficiency does not affect the apoptotic profile of 
primary thymocytes incubated with dexamethasone. They also did not found differences in 
thymocyte population between LCN2 deficient and wild type mice. 
We report here that thymic LCN2 is present through the mouse lifetime (at least till 
the age on one year), with the protein expression being more evident in the P16-P60 
period, thus coinciding with the animal sexual maturation. It is known that the size and 
activity (T cell formation) of the organ increases until sexual maturity (Pearse 2006). The 
organ then gradually atrophies due to circulating sex hormones, with functional thymic 
tissue being replaced by fat. Consequently, the thymic T cell output also decreases with 
age (Savino 2000; Sutherland et al. 2005). The observation that the herein described peak 
of thymic LCN2 is coincident with the organ higher activity in terms of T cell formation 
further supports the possibility of a LCN2 participation in such processes.  
The data regarding the functional aspects of thymic LCN2 is scarce and not 
consensual. Clearly more work is required in order to better understand the role of LCN2 
in the functioning of the organ.  
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5 
Conclusions, Future perspectives and Final Remarks 
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5.1.  Conclusions 
We report here that LCN2 presence and distribution in various organs vary with age 
and physiological state. We hypothesize that the observed LCN2 expression in the fetal 
and newborn liver is likely linked to the hematopoietic processes that are known to occur 
in this organ. The prominent LCN2 presence in the control perinatal kidney may reflect the 
involvement of the protein in the organ development, possibly through iron delivery. The 
overall LCN2 induction by LPS in all of the studied tissues (with the exception of the 
thymus) in the post-natal period suggests that the mechanisms by which the protein is 
induced and its biological functions may be preserved through age in each organ. 
5.2. Future perspectives and final remarks 
With this work we provide some previously unreported observations that ultimately 
raise new questions regarding LCN2 biology. Among others, it would be relevant to 
address the following issues in the future: 
? What is the contribution of LCN2 for kidney development? 
? What is the functional and biological significance of age-dependent variation in the 
kidney response, regarding LCN2 expression, to the LPS endotoxin? 
? How does the lack of LCN2 synthesis by CP epithelia after an LPS stimulus in 
newborn mice impacts the overall brain response to infection and the CSF iron balance? 
? Why is the LCN2 expression lower in the embryonic liver of dam from LPS 
injected pregnants? 
 
Our findings further suggest that future studies regarding LCN2 relevance in certain 
tissues should consider the age factor. Although LCN2 biology is not fully understood, 
growing evidence indicates that the protein is pertinent in many aspects of mammalian life. 
The protein has promising clinical applications in perspective, namely in the context of 
kidney injury. Further research is required to define the precise functions of LCN2 and to 
possible unveil new clinical application for the protein.  
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